≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Tick-borne viral encephalitis, including avohilmo

Endpoint Browser PheWeb

AB1_TICK_BORNE_ENCEPHALITIS_WIDE

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Primary healthcare outpatient: ICD-10 — A84
  • Hospital discharge: ICD-10 — A84
  • Hospital discharge: ICD-9 — 06[3]
  • Hospital discharge: ICD-8 — 06[3]
  • Cause of death: ICD-10 — A84
  • Cause of death: ICD-9 — 06[3]
  • Cause of death: ICD-8 — 06[3]

3 out of 7 registries used, show all original rules.

218

4. Check minimum number of events

None

218

5. Include endpoints

None

218

6. Filter based on genotype QC (FinnGen only)

200

Control definitions (FinnGen only)

Control exclude
AB1_VIRAL_CNS

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF13

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 200 112 88
Unadjusted period prevalence (%) 0.04 0.04 0.04
Median age at first event (years) 57.18 55.94 58.76

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
218
Matched controls
2180
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
A84.8
ICD-10 Finland
Other tick-borne viral encephalitis
+∞
115.1
100
*
A84.9
ICD-10 Finland
Tick-borne viral encephalitis, unspecified
+∞
94.9
84
*
A86
ICD-10 Finland
Unspecified viral encephalitis
+∞
39.8
37
*
R50.9
ICD-10 Finland
Fever, unspecified
6.5
38.8
88
206
TAB00
NOMESCO Finland
Lumbar puncture
9.6
36.9
49
64
XA800
NOMESCO Finland
Neuropsychological investigation
10.0
35.6
45
55
A69.2
ICD-10 Finland
Lyme disease
8.3
29.2
43
63
A87.9
ICD-10 Finland
Viral meningitis, unspecified
+∞
26.6
25
*
AA1AD
NOMESCO Finland
CT of head and brain
4.3
25.4
106
391
A84.1
ICD-10 Finland
Central European tick-borne encephalitis
+∞
23.3
22
*
A84
ICD-10 Finland
Tick-borne viral encephalitis
+∞
23.3
22
*
R4120
NOMESCO Finland
Occupational therapy
5.6
18.9
40
84
G04.9
ICD-10 Finland
Encephalitis, myelitis and encephalomyelitis, unspecified
+∞
13.7
13
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.7
11.4
129
764
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.8
11.3
38
114
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.7
11.1
40
126
B34.9
ICD-10 Finland
Viral infection, unspecified
10.0
10.8
21
23
N71
ICPC
Meningitis/encephalitis
+∞
10.5
10
*
S12
ICPC
Insect bite/sting
3.7
10.3
36
111
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
7.5
9.6
22
32
0632A
ICD-9 Finland
Tick-borne viral encephalitis, Central European encephalitis[PUUTIAISEN VÄLITTÄMÄ ENKEFALIITTI (KUMLINGE)]
+∞
9.4
9
*
G03.9
ICD-10 Finland
Meningitis, unspecified
26.1
7.6
10
*
G01*A69.2
ICD-10 Finland
Meningitis (in) Lyme disease
+∞
7.3
7
*
R4110
NOMESCO Finland
Physiotherapy
2.2
6.6
75
422
J01CA04
ATC
amoxicillin; systemic
2.8
6.3
190
1548
R4150
NOMESCO Finland
Neuropsychological rehabilitation
13.0
6.1
10
8
N29
ICPC
Neurological sympt/complt other
10.5
6.1
11
11

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2.3e-01
2.8e-01
2.7e+00
5.4e+00
2.5e+00
3.0e-01
8.3e-03
cases:55.71%
controls:50.02%
cases:40.95%
controls:34.30%
cases:48.10%
controls:5.67%
cases:40.00%
controls:0.29%
cases:45.15%
controls:6.26%
cases:41.21%
controls:34.09%
cases:52.76%
controls:52.55%
117
1050
93
1049
86
720
124
1379
101
119
109
1980
84
6
126
2093
93
130
113
1948
75
630
107
1218
67
639
60
577
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2.3e-01
2.6e-01
2.7e+00
5.4e+00
2.5e+00
3.1e-01
-1.8e-02
cases:56.19%
controls:50.50%
cases:40.95%
controls:34.73%
cases:48.10%
controls:5.91%
cases:40.00%
controls:0.29%
cases:45.63%
controls:6.35%
cases:41.76%
controls:34.42%
cases:52.76%
controls:53.21%
118
1060
92
1039
86
729
124
1370
101
124
109
1975
84
6
126
2093
94
132
112
1946
76
636
106
1212
67
647
60
569
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
6.5e-02
1.6e-01
2.6e+00
5.2e+00
2.3e+00
2.3e-01
-9.8e-02
cases:58.10%
controls:56.50%
cases:46.67%
controls:42.69%
cases:50.00%
controls:7.05%
cases:38.57%
controls:0.33%
cases:45.15%
controls:7.89%
cases:46.15%
controls:40.48%
cases:55.91%
controls:58.31%
122
1186
88
913
98
896
112
1203
105
148
105
1951
81
7
129
2092
93
164
113
1914
84
748
98
1100
71
709
56
507
Platelets [#/volume] in Blood
26515-7 [3007461]
1.1e-01
1.4e-01
2.5e+00
5.2e+00
2.2e+00
2.4e-01
-2.1e-02
cases:64.29%
controls:61.74%
cases:51.43%
controls:48.02%
cases:54.29%
controls:9.05%
cases:40.95%
controls:0.38%
cases:48.06%
controls:9.58%
cases:51.10%
controls:45.18%
cases:61.42%
controls:61.92%
135
1296
75
803
108
1008
102
1091
114
190
96
1909
86
8
124
2091
99
199
107
1879
93
835
89
1013
78
753
49
463
MCH [Entitic mass]
28539-5 [3035941]
1.2e-01
1.4e-01
2.5e+00
5.2e+00
2.2e+00
2.4e-01
-2.8e-02
cases:64.76%
controls:61.89%
cases:51.43%
controls:47.88%
cases:54.29%
controls:9.05%
cases:40.95%
controls:0.38%
cases:48.06%
controls:9.62%
cases:51.10%
controls:45.24%
cases:61.42%
controls:62.09%
136
1299
74
800
108
1005
102
1094
114
190
96
1909
86
8
124
2091
99
200
107
1878
93
836
89
1012
78
755
49
461
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.2e-01
1.4e-01
2.5e+00
5.2e+00
2.2e+00
2.2e-01
-2.5e-02
cases:64.76%
controls:61.93%
cases:51.43%
controls:47.93%
cases:54.29%
controls:9.05%
cases:40.95%
controls:0.38%
cases:48.06%
controls:9.62%
cases:50.55%
controls:45.18%
cases:61.42%
controls:62.01%
136
1300
74
799
108
1006
102
1093
114
190
96
1909
86
8
124
2091
99
200
107
1878
92
835
90
1013
78
754
49
462
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.2e-01
1.4e-01
2.5e+00
5.2e+00
2.2e+00
2.4e-01
-2.8e-02
cases:64.76%
controls:61.93%
cases:51.43%
controls:48.02%
cases:54.29%
controls:9.10%
cases:40.95%
controls:0.38%
cases:48.06%
controls:9.62%
cases:51.10%
controls:45.24%
cases:61.42%
controls:62.09%
136
1300
74
799
108
1008
102
1091
114
191
96
1908
86
8
124
2091
99
200
107
1878
93
836
89
1012
78
755
49
461
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.2e-01
1.4e-01
2.5e+00
5.2e+00
2.2e+00
2.4e-01
-2.8e-02
cases:64.76%
controls:61.93%
cases:51.43%
controls:47.98%
cases:54.29%
controls:9.10%
cases:40.95%
controls:0.38%
cases:48.06%
controls:9.62%
cases:51.10%
controls:45.18%
cases:61.42%
controls:62.09%
136
1300
74
799
108
1007
102
1092
114
191
96
1908
86
8
124
2091
99
200
107
1878
93
835
89
1013
78
755
49
461
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.2e-01
1.4e-01
2.5e+00
5.2e+00
2.2e+00
2.4e-01
-2.8e-02
cases:64.76%
controls:61.98%
cases:51.43%
controls:48.02%
cases:54.29%
controls:9.10%
cases:40.95%
controls:0.38%
cases:48.06%
controls:9.62%
cases:51.10%
controls:45.18%
cases:61.42%
controls:62.09%
136
1301
74
798
108
1008
102
1091
114
191
96
1908
86
8
124
2091
99
200
107
1878
93
835
89
1013
78
755
49
461
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.2e-01
1.3e-01
2.5e+00
5.2e+00
2.2e+00
2.4e-01
-3.2e-02
cases:64.76%
controls:61.93%
cases:51.43%
controls:48.12%
cases:54.29%
controls:9.15%
cases:40.95%
controls:0.38%
cases:48.06%
controls:9.67%
cases:51.10%
controls:45.24%
cases:61.42%
controls:62.17%
136
1300
74
799
108
1010
102
1089
114
192
96
1907
86
8
124
2091
99
201
107
1877
93
836
89
1012
78
756
49
460
Neurology
13 [38004458]
-8.4e-02
6.3e-01
2.7e+00
1.0e+50
3.5e+00
3.0e+00
6.1e-01
cases:10.48%
controls:11.29%
cases:7.14%
controls:3.95%
cases:9.52%
controls:0.71%
cases:46.67%
controls:0.00%
cases:28.64%
controls:1.15%
cases:46.70%
controls:4.00%
cases:14.96%
controls:8.72%
22
237
188
1862
15
83
195
2016
20
15
190
2084
98
0
112
2099
59
24
147
2054
85
74
97
1774
19
106
108
1110
Laboratory Visit
OMOP4822461 [32036]
2.0e-02
2.1e-01
2.0e+00
4.5e+00
1.7e+00
7.8e-02
-2.3e-02
cases:67.62%
controls:67.17%
cases:63.81%
controls:58.93%
cases:59.05%
controls:16.01%
cases:50.95%
controls:1.10%
cases:51.46%
controls:16.79%
cases:57.69%
controls:55.79%
cases:66.93%
controls:67.43%
142
1410
68
689
134
1237
76
862
124
336
86
1763
107
23
103
2076
106
349
100
1729
105
1031
77
817
85
820
42
396
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
2.0e-01
1.9e-01
2.2e+00
3.9e+00
1.8e+00
1.8e-01
-1.3e-01
cases:60.00%
controls:55.07%
cases:43.81%
controls:39.11%
cases:33.81%
controls:5.48%
cases:16.19%
controls:0.38%
cases:30.58%
controls:6.83%
cases:39.56%
controls:35.39%
cases:52.76%
controls:55.92%
126
1156
84
943
92
821
118
1278
71
115
139
1984
34
8
176
2091
63
142
143
1936
72
654
110
1194
67
680
60
536
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
4.4e-01
6.9e-01
4.2e+00
1.0e+50
3.2e+00
3.9e-01
-2.7e-01
cases:11.90%
controls:8.00%
cases:7.62%
controls:3.95%
cases:16.67%
controls:0.29%
cases:6.19%
controls:0.00%
cases:9.71%
controls:0.43%
cases:4.95%
controls:3.41%
cases:6.30%
controls:8.06%
25
168
185
1931
16
83
194
2016
35
6
175
2093
13
0
197
2099
20
9
186
2069
9
63
173
1785
8
98
119
1118
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
2.2e-01
1.6e-01
4.1e+00
1.0e+50
3.4e+00
1.0e-01
-3.6e-01
cases:12.86%
controls:10.58%
cases:5.71%
controls:4.91%
cases:18.10%
controls:0.38%
cases:6.67%
controls:0.00%
cases:10.19%
controls:0.38%
cases:4.95%
controls:4.49%
cases:7.87%
controls:10.94%
27
222
183
1877
12
103
198
1996
38
8
172
2091
14
0
196
2099
21
8
185
2070
9
83
173
1765
10
133
117
1083
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
2.9e-01
6.5e-01
4.1e+00
1.0e+50
3.3e+00
1.5e-01
-3.8e-01
cases:11.90%
controls:9.19%
cases:8.10%
controls:4.38%
cases:18.57%
controls:0.38%
cases:6.67%
controls:0.00%
cases:10.19%
controls:0.43%
cases:4.95%
controls:4.27%
cases:7.09%
controls:10.03%
25
193
185
1906
17
92
193
2007
39
8
171
2091
14
0
196
2099
21
9
185
2069
9
79
173
1769
9
122
118
1094
Bacteria [Presence] in Urine
87829-8 [36304419]
5.1e-01
6.8e-01
4.1e+00
1.0e+50
3.2e+00
4.0e-01
-2.8e-01
cases:12.38%
controls:7.81%
cases:7.14%
controls:3.76%
cases:15.24%
controls:0.29%
cases:5.71%
controls:0.00%
cases:8.74%
controls:0.38%
cases:4.40%
controls:2.98%
cases:6.30%
controls:8.14%
26
164
184
1935
15
79
195
2020
32
6
178
2093
12
0
198
2099
18
8
188
2070
8
55
174
1793
8
99
119
1117
Leukocytes [#/volume] in Urine
30405-5 [3018095]
5.3e-01
6.5e-01
4.0e+00
1.0e+50
2.9e+00
4.8e-02
-4.3e-01
cases:16.67%
controls:10.53%
cases:10.48%
controls:5.76%
cases:21.90%
controls:0.52%
cases:6.67%
controls:0.00%
cases:9.71%
controls:0.58%
cases:5.49%
controls:5.25%
cases:7.87%
controls:11.60%
35
221
175
1878
22
121
188
1978
46
11
164
2088
14
0
196
2099
20
12
186
2066
10
97
172
1751
10
141
117
1075
Differential panel, method unspecified - Blood
69738-3 [42870588]
3.6e-01
3.5e-01
2.9e+00
—
3.0e+00
8.7e-01
2.6e-01
cases:17.14%
controls:12.63%
cases:8.10%
controls:5.86%
cases:16.67%
controls:1.05%
—
—
cases:17.48%
controls:1.01%
cases:12.64%
controls:5.74%
cases:14.17%
controls:11.27%
36
265
174
1834
17
123
193
1976
35
22
175
2077
—
36
21
170
2057
23
106
159
1742
18
137
109
1079
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
4.7e-02
1.5e-01
3.6e+00
—
3.0e+00
2.2e-01
2.3e-01
cases:9.05%
controls:8.67%
cases:2.86%
controls:2.48%
cases:10.95%
controls:0.33%
—
—
cases:8.25%
controls:0.43%
cases:3.30%
controls:2.65%
cases:7.87%
controls:6.33%
19
182
191
1917
6
52
204
2047
23
7
187
2092
—
17
9
189
2069
6
49
176
1799
10
77
117
1139
Internal Medicine
11 [38004456]
1.5e-01
5.0e-01
3.0e+00
1.0e+50
2.4e+00
1.1e+00
3.3e-01
cases:20.00%
controls:17.68%
cases:10.48%
controls:6.62%
cases:18.10%
controls:1.05%
cases:21.90%
controls:0.00%
cases:9.71%
controls:1.01%
cases:14.84%
controls:5.74%
cases:20.47%
controls:15.63%
42
371
168
1728
22
139
188
1960
38
22
172
2077
46
0
164
2099
20
21
186
2057
27
106
155
1742
26
190
101
1026
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
2.1e-01
-5.2e-02
3.9e+00
—
2.5e+00
3.7e-01
-2.9e-01
cases:10.00%
controls:8.24%
cases:4.76%
controls:5.00%
cases:11.90%
controls:0.29%
—
—
cases:3.88%
controls:0.34%
cases:4.95%
controls:3.46%
cases:7.09%
controls:9.21%
21
173
189
1926
10
105
200
1994
25
6
185
2093
—
8
7
198
2071
9
64
173
1784
9
112
118
1104
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
4.7e-01
8.3e-01
3.1e+00
1.0e+50
3.2e+00
6.6e-01
9.1e-02
cases:12.86%
controls:8.48%
cases:8.10%
controls:3.72%
cases:13.33%
controls:0.71%
cases:12.38%
controls:0.00%
cases:13.59%
controls:0.63%
cases:5.49%
controls:2.92%
cases:7.87%
controls:7.24%
27
178
183
1921
17
78
193
2021
28
15
182
2084
26
0
184
2099
28
13
178
2065
10
54
172
1794
10
88
117
1128
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
2.6e-01
6.7e-01
3.4e+00
—
2.8e+00
1.7e-01
—
cases:6.67%
controls:5.24%
cases:4.29%
controls:2.24%
cases:6.67%
controls:0.24%
—
—
cases:4.37%
controls:0.29%
cases:2.75%
controls:2.33%
—
—
14
110
196
1989
9
47
201
2052
14
5
196
2094
—
9
6
197
2072
5
43
177
1805
—
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
3.6e-01
2.8e-01
3.8e+00
—
2.4e+00
-7.4e-02
1.0e-01
cases:29.52%
controls:22.63%
cases:12.86%
controls:10.00%
cases:32.38%
controls:1.10%
—
—
cases:10.68%
controls:1.11%
cases:8.24%
controls:8.82%
cases:22.05%
controls:20.31%
62
475
148
1624
27
210
183
1889
68
23
142
2076
—
22
23
184
2055
15
163
167
1685
28
247
99
969
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
-1.9e-01
—
2.7e+00
—
3.4e+00
—
—
cases:4.29%
controls:5.15%
—
—
cases:3.33%
controls:0.24%
—
—
cases:6.80%
controls:0.24%
—
—
—
—
9
108
201
1991
—
7
5
203
2094
—
14
5
192
2073
—
—
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
2.0e-01
1.4e-01
3.0e+00
—
3.0e+00
3.8e-01
5.8e-02
cases:53.33%
controls:48.40%
cases:30.95%
controls:27.97%
cases:54.29%
controls:5.62%
—
—
cases:45.63%
controls:4.19%
cases:33.52%
controls:25.65%
cases:47.24%
controls:45.81%
112
1016
98
1083
65
587
145
1512
114
118
96
1981
—
94
87
112
1991
61
474
121
1374
60
557
67
659
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
3.4e-01
2.6e-01
3.4e+00
1.0e+50
2.5e+00
-2.2e-01
-9.2e-01
cases:10.48%
controls:7.67%
cases:5.71%
controls:4.48%
cases:10.48%
controls:0.38%
cases:3.33%
controls:0.00%
cases:4.37%
controls:0.38%
cases:2.75%
controls:3.41%
cases:3.94%
controls:9.29%
22
161
188
1938
12
94
198
2005
22
8
188
2091
7
0
203
2099
9
8
197
2070
5
63
177
1785
5
113
122
1103
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
3.7e-01
1.1e-01
2.9e+00
—
2.8e+00
6.1e-01
-1.4e-01
cases:26.19%
controls:19.68%
cases:11.90%
controls:10.81%
cases:22.38%
controls:1.57%
—
—
cases:21.84%
controls:1.68%
cases:15.93%
controls:9.36%
cases:16.54%
controls:18.59%
55
413
155
1686
25
227
185
1872
47
33
163
2066
—
45
35
161
2043
29
173
153
1675
21
226
106
990
Monocytes [#/volume] in Blood
26484-6 [3001604]
4.0e-01
8.2e-02
2.8e+00
—
2.8e+00
6.4e-01
-1.4e-01
cases:26.19%
controls:19.15%
cases:11.43%
controls:10.62%
cases:21.43%
controls:1.57%
—
—
cases:21.84%
controls:1.64%
cases:15.93%
controls:9.09%
cases:16.54%
controls:18.59%
55
402
155
1697
24
223
186
1876
45
33
165
2066
—
45
34
161
2044
29
168
153
1680
21
226
106
990
Basophils [#/volume] in Blood
26444-0 [3006315]
4.0e-01
1.3e-01
2.8e+00
—
2.8e+00
6.5e-01
-1.5e-01
cases:26.19%
controls:19.20%
cases:11.90%
controls:10.62%
cases:21.90%
controls:1.62%
—
—
cases:21.84%
controls:1.64%
cases:15.93%
controls:9.04%
cases:16.54%
controls:18.67%
55
403
155
1696
25
223
185
1876
46
34
164
2065
—
45
34
161
2044
29
167
153
1681
21
227
106
989
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
2.8e-01
1.9e-01
2.9e+00
—
2.8e+00
6.9e-01
-3.4e-02
cases:22.38%
controls:17.96%
cases:11.43%
controls:9.62%
cases:20.95%
controls:1.48%
—
—
cases:21.36%
controls:1.68%
cases:15.38%
controls:8.39%
cases:15.75%
controls:16.20%
47
377
163
1722
24
202
186
1897
44
31
166
2068
—
44
35
162
2043
28
155
154
1693
20
197
107
1019
Monocytes/Leukocytes in Blood
26485-3 [3019069]
3.5e-01
2.5e-01
2.8e+00
—
2.8e+00
7.0e-01
-4.0e-02
cases:23.81%
controls:18.01%
cases:11.90%
controls:9.53%
cases:20.48%
controls:1.52%
—
—
cases:21.36%
controls:1.64%
cases:15.38%
controls:8.28%
cases:15.75%
controls:16.28%
50
378
160
1721
25
200
185
1899
43
32
167
2067
—
44
34
162
2044
28
153
154
1695
20
198
107
1018
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
3.4e-01
1.7e-01
2.8e+00
—
2.8e+00
6.7e-01
-6.4e-02
cases:23.81%
controls:18.25%
cases:11.43%
controls:9.81%
cases:20.95%
controls:1.52%
—
—
cases:21.36%
controls:1.68%
cases:15.38%
controls:8.50%
cases:15.75%
controls:16.61%
50
383
160
1716
24
206
186
1893
44
32
166
2067
—
44
35
162
2043
28
157
154
1691
20
202
107
1014
Basophils/Leukocytes in Blood
30180-4 [3022096]
3.6e-01
2.6e-01
2.8e+00
—
2.8e+00
7.1e-01
-4.6e-02
cases:23.81%
controls:17.87%
cases:11.90%
controls:9.43%
cases:20.48%
controls:1.57%
—
—
cases:21.84%
controls:1.64%
cases:15.38%
controls:8.23%
cases:15.75%
controls:16.37%
50
375
160
1724
25
198
185
1901
43
33
167
2066
—
45
34
161
2044
28
152
154
1696
20
199
107
1017
Eosinophils [#/volume] in Blood
26449-9 [3013115]
3.8e-01
1.6e-01
2.8e+00
—
2.8e+00
5.9e-01
-1.0e-01
cases:26.67%
controls:19.96%
cases:12.38%
controls:10.77%
cases:22.38%
controls:1.67%
—
—
cases:22.33%
controls:1.78%
cases:15.93%
controls:9.52%
cases:17.32%
controls:18.83%
56
419
154
1680
26
226
184
1873
47
35
163
2064
—
46
37
160
2041
29
176
153
1672
22
229
105
987
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
3.7e-01
2.5e-01
2.8e+00
—
2.8e+00
7.0e-01
-3.4e-02
cases:23.81%
controls:17.82%
cases:11.90%
controls:9.48%
cases:20.48%
controls:1.57%
—
—
cases:21.36%
controls:1.64%
cases:15.38%
controls:8.28%
cases:15.75%
controls:16.20%
50
374
160
1725
25
199
185
1900
43
33
167
2066
—
44
34
162
2044
28
153
154
1695
20
197
107
1019
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
6.6e-02
4.3e-02
3.2e+00
1.0e+50
2.3e+00
2.4e-01
-1.6e-01
cases:20.00%
controls:18.96%
cases:8.57%
controls:8.24%
cases:18.10%
controls:0.86%
cases:10.00%
controls:0.00%
cases:7.77%
controls:0.82%
cases:9.34%
controls:7.47%
cases:14.96%
controls:17.11%
42
398
168
1701
18
173
192
1926
38
18
172
2081
21
0
189
2099
16
17
190
2061
17
138
165
1710
19
208
108
1008
pH of Urine
2756-5 [3015736]
9.2e-02
-6.0e-02
3.2e+00
1.0e+50
2.3e+00
-3.7e-01
-6.9e-01
cases:14.29%
controls:13.20%
cases:6.67%
controls:7.05%
cases:12.38%
controls:0.57%
cases:4.29%
controls:0.00%
cases:4.37%
controls:0.43%
cases:3.85%
controls:5.47%
cases:7.87%
controls:14.56%
30
277
180
1822
14
148
196
1951
26
12
184
2087
9
0
201
2099
9
9
197
2069
7
101
175
1747
10
177
117
1039
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
8.4e-02
-5.8e-02
3.5e+00
—
2.0e+00
8.3e-02
2.9e-02
cases:27.62%
controls:25.96%
cases:11.90%
controls:12.53%
cases:26.67%
controls:1.10%
—
—
cases:8.74%
controls:1.30%
cases:11.54%
controls:10.71%
cases:22.05%
controls:21.55%
58
545
152
1554
25
263
185
1836
56
23
154
2076
—
18
27
188
2051
21
198
161
1650
28
262
99
954
doxycycline; oral, parenteral
J01AA02 [21602800]
1.7e-01
-1.7e-01
2.9e+00
—
2.5e+00
4.5e-01
1.0e-01
cases:17.14%
controls:14.86%
cases:4.29%
controls:5.05%
cases:6.67%
controls:0.38%
—
—
cases:7.28%
controls:0.63%
cases:6.04%
controls:3.95%
cases:14.17%
controls:12.99%
36
312
174
1787
9
106
201
1993
14
8
196
2091
—
15
13
191
2065
11
73
171
1775
18
158
109
1058
Case Management Agency
251B00000X [38004193]
-8.1e-02
4.8e-02
1.3e+00
3.6e+00
5.4e-01
2.5e-01
2.5e-02
cases:76.67%
controls:78.08%
cases:74.76%
controls:73.84%
cases:64.76%
controls:33.59%
cases:47.62%
controls:2.53%
cases:47.09%
controls:34.12%
cases:79.12%
controls:74.73%
cases:79.53%
controls:79.11%
161
1639
49
460
157
1550
53
549
136
705
74
1394
100
53
110
2046
97
709
109
1369
144
1381
38
467
101
962
26
254
Emergency Room and Inpatient Visit
ERIP [262]
4.9e-02
6.4e-02
2.9e+00
1.0e+50
2.4e+00
8.3e-02
2.8e-02
cases:10.95%
controls:10.48%
cases:4.76%
controls:4.48%
cases:9.05%
controls:0.52%
cases:30.00%
controls:0.00%
cases:7.28%
controls:0.72%
cases:4.40%
controls:4.06%
cases:9.45%
controls:9.21%
23
220
187
1879
10
94
200
2005
19
11
191
2088
63
0
147
2099
15
15
191
2063
8
75
174
1773
12
112
115
1104
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
-1.9e-01
4.5e-02
3.2e+00
1.0e+50
2.0e+00
-6.3e-02
-2.5e-02
cases:8.10%
controls:9.62%
cases:3.33%
controls:3.19%
cases:5.71%
controls:0.24%
cases:3.81%
controls:0.00%
cases:2.91%
controls:0.38%
cases:2.75%
controls:2.92%
cases:7.87%
controls:8.06%
17
202
193
1897
7
67
203
2032
12
5
198
2094
8
0
202
2099
6
8
200
2070
5
54
177
1794
10
98
117
1118
Emergency Room Visit
ER [9203]
1.9e-01
2.8e-01
3.0e+00
1.0e+50
2.2e+00
-4.0e-01
1.4e-01
cases:32.86%
controls:28.87%
cases:12.38%
controls:9.67%
cases:20.00%
controls:1.29%
cases:38.57%
controls:0.00%
cases:7.77%
controls:0.91%
cases:5.49%
controls:8.01%
cases:25.98%
controls:23.44%
69
606
141
1493
26
203
184
1896
42
27
168
2072
81
0
129
2099
16
19
190
2059
10
148
172
1700
33
285
94
931
Short blood count panel - Blood
55429-5 [40758558]
4.9e-01
4.3e-01
2.7e+00
—
2.4e+00
5.7e-01
5.3e-01
cases:12.86%
controls:8.29%
cases:6.67%
controls:4.43%
cases:6.19%
controls:0.43%
—
—
cases:7.28%
controls:0.72%
cases:7.69%
controls:4.49%
cases:13.39%
controls:8.31%
27
174
183
1925
14
93
196
2006
13
9
197
2090
—
15
15
191
2063
14
83
168
1765
17
101
110
1115
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
-2.7e-01
-2.8e-01
3.2e+00
—
1.8e+00
1.2e-01
-4.6e-01
cases:14.29%
controls:17.91%
cases:7.62%
controls:9.81%
cases:17.62%
controls:0.86%
—
—
cases:5.83%
controls:0.96%
cases:9.34%
controls:8.39%
cases:13.39%
controls:19.65%
30
376
180
1723
16
206
194
1893
37
18
173
2081
—
12
20
194
2058
17
155
165
1693
17
239
110
977
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
3.4e-01
2.3e-01
2.7e+00
—
2.4e+00
4.1e-01
2.0e-01
cases:19.05%
controls:14.39%
cases:8.57%
controls:6.91%
cases:10.95%
controls:0.86%
—
—
cases:7.77%
controls:0.77%
cases:8.79%
controls:6.01%
cases:15.75%
controls:13.32%
40
302
170
1797
18
145
192
1954
23
18
187
2081
—
16
16
190
2062
16
111
166
1737
20
162
107
1054
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
-2.5e-01
-2.4e-01
3.2e+00
—
1.8e+00
1.3e-01
-5.1e-01
cases:14.29%
controls:17.63%
cases:7.62%
controls:9.53%
cases:17.62%
controls:0.86%
—
—
cases:5.34%
controls:0.91%
cases:9.34%
controls:8.33%
cases:12.60%
controls:19.33%
30
370
180
1729
16
200
194
1899
37
18
173
2081
—
11
19
195
2059
17
154
165
1694
16
235
111
981
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
-3.0e-01
-2.7e-01
3.2e+00
—
1.8e+00
1.4e-01
-3.3e-01
cases:14.29%
controls:18.39%
cases:7.62%
controls:9.72%
cases:17.62%
controls:0.86%
—
—
cases:5.34%
controls:0.96%
cases:9.34%
controls:8.23%
cases:14.96%
controls:19.65%
30
386
180
1713
16
204
194
1895
37
18
173
2081
—
11
20
195
2058
17
152
165
1696
19
239
108
977
Supplier / Service Provider
OMOP5117446 [33004]
-4.3e-01
-5.0e-01
—
—
—
2.3e+00
2.7e+00
cases:23.33%
controls:31.87%
cases:4.76%
controls:7.62%
—
—
—
—
—
—
cases:7.14%
controls:0.76%
cases:13.39%
controls:1.07%
49
669
161
1430
10
160
200
1939
—
—
—
13
14
169
1834
17
13
110
1203
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
3.6e-01
1.7e-01
2.5e+00
—
2.4e+00
5.3e-01
1.4e-01
cases:29.52%
controls:22.68%
cases:14.29%
controls:12.34%
cases:23.81%
controls:2.43%
—
—
cases:22.33%
controls:2.55%
cases:15.93%
controls:10.06%
cases:21.26%
controls:19.08%
62
476
148
1623
30
259
180
1840
50
51
160
2048
—
46
53
160
2025
29
186
153
1662
27
232
100
984
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
2.0e-01
4.3e-01
2.6e+00
—
2.3e+00
4.1e-01
-1.2e-01
cases:48.10%
controls:43.12%
cases:40.48%
controls:30.59%
cases:45.24%
controls:5.57%
—
—
cases:37.86%
controls:5.92%
cases:39.56%
controls:30.19%
cases:41.73%
controls:44.74%
101
905
109
1194
85
642
125
1457
95
117
115
1982
—
78
123
128
1955
72
558
110
1290
53
544
74
672
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
8.9e-02
-2.2e-01
2.4e+00
—
2.3e+00
4.8e-01
6.3e-02
cases:30.48%
controls:28.63%
cases:12.38%
controls:14.91%
cases:20.48%
controls:2.19%
—
—
cases:13.11%
controls:1.54%
cases:18.13%
controls:12.07%
cases:27.56%
controls:26.32%
64
601
146
1498
26
313
184
1786
43
46
167
2053
—
27
32
179
2046
33
223
149
1625
35
320
92
896
Normoblasts [#/volume] in Blood
715-3 [3021589]
2.4e-01
1.2e-02
2.5e+00
—
2.3e+00
2.9e-01
-2.8e-01
cases:21.43%
controls:17.72%
cases:12.86%
controls:12.72%
cases:19.52%
controls:2.05%
—
—
cases:20.87%
controls:2.69%
cases:14.84%
controls:11.58%
cases:13.39%
controls:17.02%
45
372
165
1727
27
267
183
1832
41
43
169
2056
—
43
56
163
2022
27
214
155
1634
17
207
110
1009
Inpatient Hospital
21 [8717]
8.0e-03
4.1e-01
2.2e+00
—
2.5e+00
4.4e-01
-2.3e-02
cases:20.95%
controls:20.82%
cases:9.05%
controls:6.19%
cases:10.48%
controls:1.24%
—
—
cases:9.71%
controls:0.91%
cases:7.69%
controls:5.09%
cases:16.54%
controls:16.86%
44
437
166
1662
19
130
191
1969
22
26
188
2073
—
20
19
186
2059
14
94
168
1754
21
205
106
1011
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
3.3e-01
2.7e-01
2.4e+00
—
2.3e+00
2.4e-01
-6.9e-02
cases:53.33%
controls:45.02%
cases:38.10%
controls:31.87%
cases:39.05%
controls:5.62%
—
—
cases:35.44%
controls:5.34%
cases:34.62%
controls:29.44%
cases:44.09%
controls:45.81%
112
945
98
1154
80
669
130
1430
82
118
128
1981
—
73
111
133
1967
63
544
119
1304
56
557
71
659
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
9.7e-02
2.1e-01
2.4e+00
—
2.0e+00
2.5e-01
4.6e-01
cases:33.81%
controls:31.68%
cases:21.90%
controls:18.48%
cases:25.71%
controls:3.00%
—
—
cases:19.90%
controls:3.13%
cases:19.78%
controls:16.13%
cases:37.80%
controls:27.63%
71
665
139
1434
46
388
164
1711
54
63
156
2036
—
41
65
165
2013
36
298
146
1550
48
336
79
880
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
2.9e-01
1.8e-01
2.4e+00
—
2.0e+00
2.2e-01
6.4e-03
cases:49.05%
controls:41.92%
cases:34.29%
controls:30.30%
cases:39.52%
controls:5.62%
—
—
cases:34.95%
controls:6.50%
cases:33.52%
controls:28.79%
cases:40.94%
controls:40.79%
103
880
107
1219
72
636
138
1463
83
118
127
1981
—
72
135
134
1943
61
532
121
1316
52
496
75
720
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
3.3e-02
3.2e-01
2.4e+00
—
2.0e+00
2.7e-01
6.0e-01
cases:19.52%
controls:19.01%
cases:11.43%
controls:8.58%
cases:16.67%
controls:1.76%
—
—
cases:11.17%
controls:1.68%
cases:9.89%
controls:7.74%
cases:24.41%
controls:15.05%
41
399
169
1700
24
180
186
1919
35
37
175
2062
—
23
35
183
2043
18
143
164
1705
31
183
96
1033
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
2.5e-01
8.1e-02
2.2e+00
—
2.2e+00
4.6e-01
7.3e-02
cases:20.00%
controls:16.34%
cases:8.57%
controls:7.96%
cases:9.52%
controls:1.14%
—
—
cases:8.25%
controls:1.01%
cases:10.99%
controls:7.25%
cases:15.75%
controls:14.80%
42
343
168
1756
18
167
192
1932
20
24
190
2075
—
17
21
189
2057
20
134
162
1714
20
180
107
1036
naproxen; oral, rectal
M01AE02 [21603968]
-6.3e-02
2.3e-01
2.3e+00
—
2.0e+00
-1.5e-01
1.2e-01
cases:8.10%
controls:8.58%
cases:3.33%
controls:2.67%
cases:3.81%
controls:0.38%
—
—
cases:3.88%
controls:0.53%
cases:2.75%
controls:3.19%
cases:7.87%
controls:7.07%
17
180
193
1919
7
56
203
2043
8
8
202
2091
—
8
11
198
2067
5
59
177
1789
10
86
117
1130
naproxcinod
M01AE18 [40254094]
-6.3e-02
2.3e-01
2.3e+00
—
2.0e+00
-1.5e-01
1.2e-01
cases:8.10%
controls:8.58%
cases:3.33%
controls:2.67%
cases:3.81%
controls:0.38%
—
—
cases:3.88%
controls:0.53%
cases:2.75%
controls:3.19%
cases:7.87%
controls:7.07%
17
180
193
1919
7
56
203
2043
8
8
202
2091
—
8
11
198
2067
5
59
177
1789
10
86
117
1130
General Practice
1 [38004446]
1.9e-01
-4.8e-01
2.2e+00
1.0e+50
2.2e+00
—
-5.0e-01
cases:14.29%
controls:12.10%
cases:2.86%
controls:4.53%
cases:4.76%
controls:0.57%
cases:3.33%
controls:0.00%
cases:4.85%
controls:0.58%
—
—
cases:7.87%
controls:12.34%
30
254
180
1845
6
95
204
2004
10
12
200
2087
7
0
203
2099
10
12
196
2066
—
10
150
117
1066
Outpatient Visit
OP [9202]
8.8e-02
6.6e-03
-3.2e-01
3.5e+00
8.0e-01
4.6e-01
6.3e-02
cases:81.90%
controls:80.56%
cases:55.71%
controls:55.55%
cases:7.14%
controls:9.58%
cases:10.95%
controls:0.38%
cases:19.90%
controls:10.01%
cases:62.09%
controls:50.76%
cases:74.80%
controls:73.60%
172
1691
38
408
117
1166
93
933
15
201
195
1898
23
8
187
2091
41
208
165
1870
113
938
69
910
95
895
32
321
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1.1e-01
1.8e-01
2.2e+00
—
2.0e+00
5.0e-01
-1.5e-01
cases:12.86%
controls:11.72%
cases:5.71%
controls:4.81%
cases:4.76%
controls:0.52%
—
—
cases:3.40%
controls:0.48%
cases:6.59%
controls:4.11%
cases:8.66%
controls:9.95%
27
246
183
1853
12
101
198
1998
10
11
200
2088
—
7
10
199
2068
12
76
170
1772
11
121
116
1095
Outpatient Hospital
22 [8756]
-5.5e-02
3.4e-01
1.7e+00
—
2.5e+00
3.2e-01
-1.8e-01
cases:15.24%
controls:15.96%
cases:5.71%
controls:4.14%
cases:3.81%
controls:0.71%
—
—
cases:3.88%
controls:0.34%
cases:4.95%
controls:3.63%
cases:10.24%
controls:12.01%
32
335
178
1764
12
87
198
2012
8
15
202
2084
—
8
7
198
2071
9
67
173
1781
13
146
114
1070
pH of Serum or Plasma
2753-2 [3018418]
3.2e-01
-5.1e-01
2.0e+00
—
2.2e+00
5.6e-01
-1.1e-02
cases:12.38%
controls:9.29%
cases:2.86%
controls:4.67%
cases:5.24%
controls:0.76%
—
—
cases:5.34%
controls:0.63%
cases:7.14%
controls:4.22%
cases:9.45%
controls:9.54%
26
195
184
1904
6
98
204
2001
11
16
199
2083
—
11
13
195
2065
13
78
169
1770
12
116
115
1100
Borrelia burgdorferi IgM Ab [Units/volume] in Serum
7818-8 [3008230]
5.3e-01
1.8e+00
—
1.0e+50
—
2.2e+00
9.5e-01
cases:3.81%
controls:2.29%
cases:3.81%
controls:0.62%
—
—
cases:16.67%
controls:0.00%
—
—
cases:4.95%
controls:0.60%
cases:3.94%
controls:1.56%
8
48
202
2051
8
13
202
2086
—
35
0
175
2099
—
9
11
173
1837
5
19
122
1197
Neuropsychological investigation
XA800 [2001300412]
—
—
—
1.0e+50
1.0e+50
4.0e+00
—
—
—
—
—
—
—
cases:3.33%
controls:0.00%
cases:5.83%
controls:0.00%
cases:14.84%
controls:0.32%
—
—
—
—
—
7
0
203
2099
12
0
194
2078
27
6
155
1842
—
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
4.4e-01
7.4e-01
3.9e+00
1.0e+50
—
—
4.9e-02
cases:7.14%
controls:4.72%
cases:5.24%
controls:2.57%
cases:12.86%
controls:0.29%
cases:5.24%
controls:0.00%
—
—
—
—
cases:5.51%
controls:5.26%
15
99
195
2000
11
54
199
2045
27
6
183
2093
11
0
199
2099
—
—
7
64
120
1152
CBC panel - Blood by Automated count
58410-2 [40761511]
2.2e-02
-1.3e-01
2.0e+00
—
1.8e+00
-1.6e-02
-5.0e-02
cases:52.38%
controls:51.83%
cases:28.57%
controls:31.35%
cases:29.05%
controls:5.19%
—
—
cases:25.24%
controls:5.20%
cases:28.57%
controls:28.90%
cases:46.46%
controls:47.70%
110
1088
100
1011
60
658
150
1441
61
109
149
1990
—
52
108
154
1970
52
534
130
1314
59
580
68
636
Borrelia burgdorferi IgG Ab [Units/volume] in Serum
7817-0 [3016888]
4.8e-01
1.8e+00
—
1.0e+50
—
2.0e+00
1.2e+00
cases:3.33%
controls:2.10%
cases:3.33%
controls:0.57%
—
—
cases:16.19%
controls:0.00%
—
—
cases:4.40%
controls:0.60%
cases:3.94%
controls:1.23%
7
44
203
2055
7
12
203
2087
—
34
0
176
2099
—
8
11
174
1837
5
15
122
1201
Bacteria identified in Blood by Culture
600-7 [3023368]
1.9e-01
5.0e-01
—
1.0e+50
3.7e+00
2.7e-01
-1.5e-01
cases:8.57%
controls:7.19%
cases:4.76%
controls:2.95%
—
—
cases:20.00%
controls:0.00%
cases:12.14%
controls:0.34%
cases:3.30%
controls:2.54%
cases:6.30%
controls:7.24%
18
151
192
1948
10
62
200
2037
—
42
0
168
2099
25
7
181
2071
6
47
176
1801
8
88
119
1128
Emergency Medicine
93 [38004510]
-4.3e-02
3.5e-01
3.6e+00
1.0e+50
1.2e+00
-2.4e-01
2.4e-01
cases:23.33%
controls:24.11%
cases:14.29%
controls:10.53%
cases:32.86%
controls:1.29%
cases:22.38%
controls:0.00%
cases:4.85%
controls:1.59%
cases:8.24%
controls:10.23%
cases:29.13%
controls:24.51%
49
506
161
1593
30
221
180
1878
69
27
141
2072
47
0
163
2099
10
33
196
2045
15
189
167
1659
37
298
90
918
Bacteria identified in Urine by Culture
630-4 [3026008]
-1.2e-01
1.9e-01
3.4e+00
—
—
2.3e-01
-5.1e-01
cases:6.67%
controls:7.43%
cases:4.29%
controls:3.57%
cases:9.05%
controls:0.33%
—
—
—
—
cases:3.85%
controls:3.08%
cases:4.72%
controls:7.65%
14
156
196
1943
9
75
201
2024
19
7
191
2092
—
—
7
57
175
1791
6
93
121
1123
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
2.5e-01
3.8e-02
1.9e+00
—
1.4e+00
-2.8e-02
-2.0e-01
cases:49.05%
controls:42.93%
cases:25.24%
controls:24.54%
cases:12.86%
controls:2.14%
—
—
cases:12.62%
controls:3.32%
cases:21.98%
controls:22.46%
cases:38.58%
controls:43.34%
103
901
107
1198
53
515
157
1584
27
45
183
2054
—
26
69
180
2009
40
415
142
1433
49
527
78
689
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
9.4e-02
2.5e-01
3.3e+00
1.0e+50
1.9e+00
-1.4e-01
-4.1e-01
cases:11.90%
controls:10.96%
cases:5.24%
controls:4.14%
cases:8.57%
controls:0.33%
cases:6.19%
controls:0.00%
cases:2.91%
controls:0.43%
cases:3.85%
controls:4.38%
cases:7.87%
controls:11.43%
25
230
185
1869
11
87
199
2012
18
7
192
2092
13
0
197
2099
6
9
200
2069
7
81
175
1767
10
139
117
1077
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
1.5e-01
1.2e-01
3.3e+00
—
1.4e+00
-5.3e-02
4.1e-01
cases:32.86%
controls:29.54%
cases:10.95%
controls:9.86%
cases:19.52%
controls:0.91%
—
—
cases:4.37%
controls:1.15%
cases:6.59%
controls:6.93%
cases:24.41%
controls:17.68%
69
620
141
1479
23
207
187
1892
41
19
169
2080
—
9
24
197
2054
12
128
170
1720
31
215
96
1001
INR in Blood by Coagulation assay
34714-6 [3032080]
-2.4e-01
1.6e-01
2.0e+00
—
1.3e+00
2.5e-01
3.0e-02
cases:12.86%
controls:15.77%
cases:8.10%
controls:7.00%
cases:12.86%
controls:2.00%
—
—
cases:7.28%
controls:2.12%
cases:8.79%
controls:6.98%
cases:14.17%
controls:13.82%
27
331
183
1768
17
147
193
1952
27
42
183
2057
—
15
44
191
2034
16
129
166
1719
18
168
109
1048
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
-2.5e-01
2.3e-01
—
—
3.2e+00
—
—
cases:4.29%
controls:5.43%
cases:2.86%
controls:2.29%
—
—
—
—
cases:5.83%
controls:0.24%
—
—
—
—
9
114
201
1985
6
48
204
2051
—
—
12
5
194
2073
—
—
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
-1.7e-01
-5.1e-02
1.9e+00
1.0e+50
1.3e+00
2.8e-01
-1.0e-01
cases:26.19%
controls:29.63%
cases:11.43%
controls:11.96%
cases:7.14%
controls:1.14%
cases:3.33%
controls:0.00%
cases:5.83%
controls:1.68%
cases:13.74%
controls:10.71%
cases:22.05%
controls:23.85%
55
622
155
1477
24
251
186
1848
15
24
195
2075
7
0
203
2099
12
35
194
2043
25
198
157
1650
28
290
99
926
Osmolality of Urine
2695-5 [3026782]
1.5e-01
1.8e-01
—
—
3.0e+00
5.0e-01
—
cases:5.71%
controls:4.95%
cases:2.38%
controls:2.00%
—
—
—
—
cases:4.85%
controls:0.24%
cases:2.75%
controls:1.68%
—
—
12
104
198
1995
5
42
205
2057
—
—
10
5
196
2073
5
31
177
1817
—
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
2.4e-01
-2.3e-02
—
—
2.9e+00
3.2e-01
-1.4e-01
cases:9.05%
controls:7.24%
cases:4.29%
controls:4.38%
—
—
—
—
cases:4.37%
controls:0.24%
cases:4.95%
controls:3.63%
cases:7.87%
controls:8.96%
19
152
191
1947
9
92
201
2007
—
—
9
5
197
2073
9
67
173
1781
10
109
117
1107
Physiotherapy
R4110 [2001310233]
4.4e-01
2.5e-01
—
1.0e+50
2.9e+00
8.0e-01
2.3e-01
cases:9.52%
controls:6.34%
cases:3.33%
controls:2.62%
—
—
cases:15.24%
controls:0.00%
cases:6.80%
controls:0.38%
cases:3.30%
controls:1.52%
cases:4.72%
controls:3.78%
20
133
190
1966
7
55
203
2044
—
32
0
178
2099
14
8
192
2070
6
28
176
1820
6
46
121
1170
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
-2.8e-02
-1.2e-01
1.6e+00
—
1.3e+00
-8.4e-02
-5.4e-01
cases:33.33%
controls:33.97%
cases:15.71%
controls:17.44%
cases:6.67%
controls:1.43%
—
—
cases:8.25%
controls:2.45%
cases:15.38%
controls:16.50%
cases:22.83%
controls:33.63%
70
713
140
1386
33
366
177
1733
14
30
196
2069
—
17
51
189
2027
28
305
154
1543
29
409
98
807
Occupational therapy
R4120 [2001310234]
—
—
—
1.0e+50
1.0e+50
2.8e+00
—
—
—
—
—
—
—
cases:10.00%
controls:0.00%
cases:5.34%
controls:0.00%
cases:4.40%
controls:0.27%
—
—
—
—
—
21
0
189
2099
11
0
195
2078
8
5
174
1843
—
Bicarbonate [Moles/volume] standard in Venous blood
19232-8 [3007628]
—
-1.0e+50
2.8e+00
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.14%
cases:3.81%
controls:0.24%
—
—
—
—
cases:0.00%
controls:1.08%
—
—
—
0
24
210
2075
8
5
202
2094
—
—
0
20
182
1828
—
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
4.0e-01
4.1e-01
—
1.0e+50
2.8e+00
—
—
cases:5.71%
controls:3.91%
cases:2.86%
controls:1.91%
—
—
cases:7.14%
controls:0.00%
cases:4.37%
controls:0.29%
—
—
—
—
12
82
198
2017
6
40
204
2059
—
15
0
195
2099
9
6
197
2072
—
—
pH of Venous blood
2746-6 [3012544]
-7.9e-02
-1.0e+50
2.7e+00
—
—
-1.0e+50
—
cases:2.38%
controls:2.57%
cases:0.00%
controls:1.52%
cases:4.29%
controls:0.29%
—
—
—
—
cases:0.00%
controls:1.52%
—
—
5
54
205
2045
0
32
210
2067
9
6
201
2093
—
—
0
28
182
1820
—
Base excess in Venous blood by calculation
1927-3 [3002032]
-2.1e-02
-1.0e+50
2.7e+00
—
—
-1.0e+50
—
cases:2.38%
controls:2.43%
cases:0.00%
controls:1.48%
cases:4.29%
controls:0.29%
—
—
—
—
cases:0.00%
controls:1.24%
—
—
5
51
205
2048
0
31
210
2068
9
6
201
2093
—
—
0
23
182
1825
—
Inpatient Visit
IP [9201]
-2.0e-01
-2.3e-02
—
1.0e+50
2.7e+00
2.6e-01
-4.8e-01
cases:10.48%
controls:12.53%
cases:4.29%
controls:4.38%
—
—
cases:6.67%
controls:0.00%
cases:5.34%
controls:0.38%
cases:4.40%
controls:3.41%
cases:7.09%
controls:10.94%
22
263
188
1836
9
92
201
2007
—
14
0
196
2099
11
8
195
2070
8
63
174
1785
9
133
118
1083
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
3.3e-01
6.9e-01
2.7e+00
—
—
—
5.3e-01
cases:8.57%
controls:6.34%
cases:4.29%
controls:2.19%
cases:5.24%
controls:0.38%
—
—
—
—
—
—
cases:8.66%
controls:5.26%
18
133
192
1966
9
46
201
2053
11
8
199
2091
—
—
—
11
64
116
1152
amoxicillin; oral, parenteral
J01CA04 [21602823]
-1.1e-02
5.0e-01
2.6e+00
1.0e+50
—
-5.0e-01
1.4e-01
cases:22.86%
controls:23.06%
cases:10.95%
controls:6.96%
cases:9.05%
controls:0.71%
cases:2.38%
controls:0.00%
—
—
cases:3.85%
controls:6.17%
cases:20.47%
controls:18.34%
48
484
162
1615
23
146
187
1953
19
15
191
2084
5
0
205
2099
—
7
114
175
1734
26
223
101
993
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
-6.2e-01
-7.1e-01
2.6e+00
—
—
-3.0e-01
-5.8e-01
cases:8.10%
controls:14.10%
cases:3.33%
controls:6.57%
cases:9.05%
controls:0.71%
—
—
—
—
cases:4.40%
controls:5.84%
cases:8.66%
controls:14.47%
17
296
193
1803
7
138
203
1961
19
15
191
2084
—
—
8
108
174
1740
11
176
116
1040
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
-2.1e-02
-1.0e+50
2.6e+00
—
—
-1.0e+50
—
cases:2.38%
controls:2.43%
cases:0.00%
controls:1.43%
cases:3.81%
controls:0.29%
—
—
—
—
cases:0.00%
controls:1.46%
—
—
5
51
205
2048
0
30
210
2069
8
6
202
2093
—
—
0
27
182
1821
—
Specific gravity of Urine by Refractometry
5810-7 [3019150]
1.3e-02
—
2.6e+00
—
—
—
—
cases:7.62%
controls:7.53%
—
—
cases:4.76%
controls:0.38%
—
—
—
—
—
—
—
—
16
158
194
1941
—
10
8
200
2091
—
—
—
—
Acute upper respiratory infection, unspecified
J06.9 [45562437]
2.7e-01
2.9e-01
2.6e+00
—
—
-2.3e-01
2.1e-01
cases:18.57%
controls:14.82%
cases:9.05%
controls:6.91%
cases:9.52%
controls:0.81%
—
—
—
—
cases:6.04%
controls:7.47%
cases:16.54%
controls:13.82%
39
311
171
1788
19
145
191
1954
20
17
190
2082
—
—
11
138
171
1710
21
168
106
1048
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
-7.5e-01
—
2.5e+00
—
—
1.4e-01
-3.0e-01
cases:5.24%
controls:10.48%
—
—
cases:5.71%
controls:0.48%
—
—
—
—
cases:4.40%
controls:3.84%
cases:7.09%
controls:9.38%
11
220
199
1879
—
12
10
198
2089
—
—
8
71
174
1777
9
114
118
1102
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
cases:2.91%
controls:0.24%
—
—
—
—
—
—
—
—
6
5
200
2073
—
—
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
4.2e-01
6.4e-01
—
1.0e+50
2.5e+00
—
—
cases:4.29%
controls:2.86%
cases:2.86%
controls:1.52%
—
—
cases:6.19%
controls:0.00%
cases:2.91%
controls:0.24%
—
—
—
—
9
60
201
2039
6
32
204
2067
—
13
0
197
2099
6
5
200
2073
—
—
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
-2.9e-02
—
1.0e+50
—
2.5e+00
1.8e+00
2.7e-01
cases:5.24%
controls:5.38%
—
—
cases:2.86%
controls:0.00%
—
—
cases:2.91%
controls:0.24%
cases:3.30%
controls:0.54%
cases:3.94%
controls:3.04%
11
113
199
1986
—
6
0
204
2099
—
6
5
200
2073
6
10
176
1838
5
37
122
1179
Cathetrisation of vein
TPH04 [2001309597]
—
6.6e-01
2.5e+00
1.0e+50
—
—
5.7e-01
—
—
cases:2.38%
controls:1.24%
cases:2.86%
controls:0.24%
cases:3.33%
controls:0.00%
—
—
—
—
cases:4.72%
controls:2.71%
—
5
26
205
2073
6
5
204
2094
7
0
203
2099
—
—
6
33
121
1183
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
—
—
1.9e+00
—
2.5e+00
-1.0e+50
—
—
—
—
—
cases:2.38%
controls:0.38%
—
—
cases:3.40%
controls:0.29%
cases:0.00%
controls:1.62%
—
—
—
—
5
8
205
2091
—
7
6
199
2072
0
30
182
1818
—
Gas panel - Venous blood
24339-4 [3000991]
2.1e-01
5.9e-01
2.5e+00
—
—
—
—
cases:2.86%
controls:2.33%
cases:2.38%
controls:1.33%
cases:3.33%
controls:0.29%
—
—
—
—
—
—
—
—
6
49
204
2050
5
28
205
2071
7
6
203
2093
—
—
—
—
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
-2.3e-01
—
—
—
2.5e+00
—
—
cases:3.33%
controls:4.14%
—
—
—
—
—
—
cases:5.34%
controls:0.48%
—
—
—
—
7
87
203
2012
—
—
—
11
10
195
2068
—
—
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
2.6e-01
7.9e-02
1.3e+00
—
2.4e+00
4.9e-01
1.6e-01
cases:17.62%
controls:14.10%
cases:6.67%
controls:6.19%
cases:2.38%
controls:0.67%
—
—
cases:6.31%
controls:0.58%
cases:8.24%
controls:5.19%
cases:15.75%
controls:13.73%
37
296
173
1803
14
130
196
1969
5
14
205
2085
—
13
12
193
2066
15
96
167
1752
20
167
107
1049
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
-7.1e-01
-5.6e-01
2.4e+00
—
—
4.0e-02
-6.0e-01
cases:5.24%
controls:10.10%
cases:2.86%
controls:4.91%
cases:6.19%
controls:0.57%
—
—
—
—
cases:4.95%
controls:4.76%
cases:6.30%
controls:10.94%
11
212
199
1887
6
103
204
1996
13
12
197
2087
—
—
9
88
173
1760
8
133
119
1083
gabapentin; oral
N02BF01 [955005]
-5.0e-04
4.6e-01
1.6e+00
—
2.4e+00
1.1e+00
5.1e-01
cases:4.29%
controls:4.29%
cases:3.81%
controls:2.43%
cases:3.33%
controls:0.67%
—
—
cases:7.28%
controls:0.72%
cases:6.04%
controls:2.11%
cases:5.51%
controls:3.37%
9
90
201
2009
8
51
202
2048
7
14
203
2085
—
15
15
191
2063
11
39
171
1809
7
41
120
1175
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
-8.1e-02
-5.3e-01
2.3e+00
—
1.3e+00
—
—
cases:8.10%
controls:8.72%
cases:2.86%
controls:4.76%
cases:4.76%
controls:0.48%
—
—
cases:2.91%
controls:0.82%
—
—
—
—
17
183
193
1916
6
100
204
1999
10
10
200
2089
—
6
17
200
2061
—
—
Neutrophils [#/volume] in Blood
26499-4 [3017732]
—
—
2.3e+00
—
—
—
—
—
—
—
—
cases:2.86%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
6
6
204
2093
—
—
—
—
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
-2.0e-02
-1.5e-01
1.1e+00
—
2.2e+00
4.7e-01
2.4e-01
cases:13.81%
controls:14.05%
cases:6.19%
controls:7.15%
cases:4.76%
controls:1.57%
—
—
cases:8.74%
controls:1.01%
cases:10.99%
controls:7.14%
cases:15.75%
controls:12.83%
29
295
181
1804
13
150
197
1949
10
33
200
2066
—
18
21
188
2057
20
132
162
1716
20
156
107
1060
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
-1.3e-02
-8.5e-02
1.1e+00
—
1.2e+00
1.7e-02
8.6e-02
cases:42.38%
controls:42.69%
cases:21.90%
controls:23.39%
cases:12.86%
controls:4.91%
—
—
cases:11.65%
controls:3.99%
cases:22.53%
controls:22.24%
cases:43.31%
controls:41.20%
89
896
121
1203
46
491
164
1608
27
103
183
1996
—
24
83
182
1995
41
411
141
1437
55
501
72
715
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
-1.9e-01
—
—
—
2.2e+00
—
—
cases:2.38%
controls:2.86%
—
—
—
—
—
—
cases:2.91%
controls:0.34%
—
—
—
—
5
60
205
2039
—
—
—
6
7
200
2071
—
—
orphenadrine (chloride); oral, parenteral
N04AB02 [21604458]
1.7e-01
—
2.2e+00
—
—
—
-1.6e-01
cases:9.52%
controls:8.15%
—
—
cases:2.86%
controls:0.33%
—
—
—
—
—
—
cases:4.72%
controls:5.51%
20
171
190
1928
—
6
7
204
2092
—
—
—
6
67
121
1149
orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]
1.7e-01
—
2.2e+00
—
—
—
-1.6e-01
cases:9.52%
controls:8.15%
—
—
cases:2.86%
controls:0.33%
—
—
—
—
—
—
cases:4.72%
controls:5.51%
20
171
190
1928
—
6
7
204
2092
—
—
—
6
67
121
1149
levetiracetam; oral, parenteral
N03AX14 [21604436]
-1.0e+50
—
—
—
2.0e+00
1.3e+00
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
cases:3.40%
controls:0.48%
cases:3.30%
controls:0.92%
—
—
0
15
210
2084
—
—
—
7
10
199
2068
6
17
176
1831
—
Pharmacy visit
OMOP4822462 [581458]
-6.5e-02
2.0e-01
8.5e-01
1.1e+00
4.7e-01
1.7e-01
1.8e-01
cases:91.90%
controls:92.38%
cases:88.10%
controls:85.85%
cases:70.48%
controls:50.50%
cases:7.62%
controls:2.62%
cases:61.65%
controls:50.14%
cases:87.91%
controls:85.98%
cases:96.06%
controls:95.31%
193
1939
17
160
185
1802
25
297
148
1060
62
1039
16
55
194
2044
127
1042
79
1036
160
1589
22
259
122
1159
5
57
12 lead EKG panel
34534-8 [3044889]
2.4e-01
1.3e-01
1.9e+00
—
—
-2.0e-01
-2.1e-01
cases:33.33%
controls:28.16%
cases:14.29%
controls:12.72%
cases:7.14%
controls:1.10%
—
—
—
—
cases:10.99%
controls:13.15%
cases:23.62%
controls:27.63%
70
591
140
1508
30
267
180
1832
15
23
195
2076
—
—
20
243
162
1605
30
336
97
880
Infectious Disease
44 [38004484]
7.6e-02
-1.0e+50
—
1.0e+50
—
1.9e+00
—
cases:3.33%
controls:3.10%
cases:0.00%
controls:0.76%
—
—
cases:8.10%
controls:0.00%
—
—
cases:5.49%
controls:0.87%
—
—
7
65
203
2034
0
16
210
2083
—
17
0
193
2099
—
10
16
172
1832
—
ibuprofen
R02AX02 [1588667]
-4.7e-03
-9.5e-02
1.8e+00
—
9.6e-01
-1.1e-01
1.6e-02
cases:41.90%
controls:42.02%
cases:17.14%
controls:18.53%
cases:11.43%
controls:2.05%
—
—
cases:5.83%
controls:2.31%
cases:15.93%
controls:17.48%
cases:36.22%
controls:35.86%
88
882
122
1217
36
389
174
1710
24
43
186
2056
—
12
48
194
2030
29
323
153
1525
46
436
81
780
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
-4.7e-03
-9.5e-02
1.8e+00
—
9.6e-01
-1.1e-01
1.6e-02
cases:41.90%
controls:42.02%
cases:17.14%
controls:18.53%
cases:11.43%
controls:2.05%
—
—
cases:5.83%
controls:2.31%
cases:15.93%
controls:17.48%
cases:36.22%
controls:35.86%
88
882
122
1217
36
389
174
1710
24
43
186
2056
—
12
48
194
2030
29
323
153
1525
46
436
81
780
Pain in limb
M79.6 [45587063]
4.6e-02
-3.9e-01
1.8e+00
—
—
-1.1e-01
-4.1e-01
cases:10.48%
controls:10.05%
cases:3.81%
controls:5.53%
cases:3.33%
controls:0.57%
—
—
—
—
cases:4.40%
controls:4.87%
cases:7.87%
controls:11.43%
22
211
188
1888
8
116
202
1983
7
12
203
2087
—
—
8
90
174
1758
10
139
117
1077
Drugs identified in Urine by Screen method Nominal
12286-1 [3011288]
1.8e+00
-1.0e+50
—
—
—
-1.0e+50
—
cases:4.29%
controls:0.76%
cases:0.00%
controls:0.29%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
9
16
201
2083
0
6
210
2093
—
—
—
0
9
182
1839
—
Other specified special examinations
Z01.8 [45581003]
4.5e-02
7.5e-01
—
—
—
1.7e+00
—
cases:3.33%
controls:3.19%
cases:2.38%
controls:1.14%
—
—
—
—
—
—
cases:5.49%
controls:1.08%
—
—
7
67
203
2032
5
24
205
2075
—
—
—
10
20
172
1828
—
No disease
A97 [2002000230]
7.4e-01
1.6e+00
—
—
—
7.2e-01
3.0e-01
cases:5.71%
controls:2.81%
cases:4.29%
controls:0.91%
—
—
—
—
—
—
cases:2.75%
controls:1.35%
cases:4.72%
controls:3.54%
12
59
198
2040
9
19
201
2080
—
—
—
5
25
177
1823
6
43
121
1173
pantoprazole; oral, parenteral
A02BC02 [21600097]
-1.2e-02
3.4e-02
1.5e-01
—
1.2e+00
-1.2e-01
-1.4e-01
cases:22.38%
controls:22.58%
cases:12.86%
controls:12.48%
cases:2.86%
controls:2.48%
—
—
cases:8.25%
controls:2.55%
cases:10.99%
controls:12.18%
cases:18.90%
controls:21.22%
47
474
163
1625
27
262
183
1837
6
52
204
2047
—
17
53
189
2025
20
225
162
1623
24
258
103
958
Pure hypercholesterolaemia
E78.0 [45542771]
8.9e-01
2.5e-01
-1.0e+50
—
—
—
2.4e-01
cases:10.95%
controls:4.81%
cases:2.86%
controls:2.24%
cases:0.00%
controls:0.24%
—
—
—
—
—
—
cases:7.09%
controls:5.67%
23
101
187
1998
6
47
204
2052
0
5
210
2094
—
—
—
9
69
118
1147
Tissue Pathology biopsy report
66121-5 [40768804]
5.9e-01
6.8e-01
-1.0e+50
—
—
9.6e-01
5.3e-01
cases:23.33%
controls:14.39%
cases:6.67%
controls:3.48%
cases:0.00%
controls:0.48%
—
—
—
—
cases:8.79%
controls:3.57%
cases:15.75%
controls:9.87%
49
302
161
1797
14
73
196
2026
0
10
210
2089
—
—
16
66
166
1782
20
120
107
1096
triptorelin; parenteral
L02AE04 [21603827]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
210
2093
—
—
—
—
—
—
Guidance concerning treatment of rash and skin
SPAT1156 [2001700257]
2.0e-01
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:2.38%
controls:1.95%
cases:0.00%
controls:0.43%
—
—
—
—
—
—
cases:0.00%
controls:0.43%
cases:0.00%
controls:1.97%
5
41
205
2058
0
9
210
2090
—
—
—
0
8
182
1840
0
24
127
1192
Digoxin [Moles/volume] in Serum or Plasma
14698-5 [3027456]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
cases:0.00%
controls:0.41%
0
7
210
2092
—
—
—
—
0
7
182
1841
0
5
127
1211
Chest pain NOS
A11 [2002000152]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
0
11
182
1837
—
Erysipelas
A46 [45561706]
3.6e-01
—
—
—
—
—
3.8e-01
cases:2.38%
controls:1.67%
—
—
—
—
—
—
—
—
—
—
cases:3.94%
controls:2.71%
5
35
205
2064
—
—
—
—
—
5
33
122
1183
Candida sp identified in Specimen by Organism specific culture
555-3 [3026389]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
210
2091
—
—
—
—
—
—
olaflur; oral
A01AA03 [21600007]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
210
2090
—
—
—
—
—
—
Nuclear Ab [Presence] in Serum
8061-4 [3004616]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
210
2089
—
—
—
—
—
—
Crystals [Presence] in Synovial fluid by Light microscopy
38458-6 [3050238]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
210
2086
—
—
—
—
—
—
metronidazole; oral, rectal
P01AB01 [21604857]
2.6e-01
3.9e-01
—
—
—
—
1.5e-01
cases:9.52%
controls:7.53%
cases:3.33%
controls:2.29%
—
—
—
—
—
—
—
—
cases:5.51%
controls:4.77%
20
158
190
1941
7
48
203
2051
—
—
—
—
7
58
120
1158
Cone beam CT of paranasal sinus
DM1AI [2001301744]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
210
2091
—
—
—
—
—
—
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
3.1e-01
2.3e-01
—
—
—
6.9e-01
-1.7e-01
cases:12.38%
controls:9.39%
cases:4.76%
controls:3.81%
—
—
—
—
—
—
cases:4.95%
controls:2.54%
cases:7.09%
controls:8.31%
26
197
184
1902
10
80
200
2019
—
—
—
9
47
173
1801
9
101
118
1115
dexamethasone and antiinfectives
S03CA01 [21605206]
—
—
-1.0e+50
—
—
-1.0e+50
4.5e-01
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
cases:0.00%
controls:0.65%
cases:3.94%
controls:2.55%
—
—
0
5
210
2094
—
—
0
12
182
1836
5
31
122
1185
Resting ECG, 12 leads
FP1B5 [2001303119]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
5
127
1211
Lumbar epidural anesthesia
WX306 [2001310796]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
7
127
1209
Other specified dermatitis
L30.8 [45581941]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
0
6
210
2093
—
—
—
—
—
Other primary coxarthrosis
M16.1 [45591741]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
—
0
15
182
1833
—
oxycodone and naloxone; oral
N02AA55 [21604265]
-4.1e-02
5.9e-01
—
—
—
—
4.2e-02
cases:2.38%
controls:2.48%
cases:2.38%
controls:1.33%
—
—
—
—
—
—
—
—
cases:3.94%
controls:3.78%
5
52
205
2047
5
28
205
2071
—
—
—
—
5
46
122
1170
Other specified counselling
Z71.8 [45581061]
4.4e-01
4.8e-01
1.6e+00
—
—
2.8e-01
-7.7e-02
cases:10.95%
controls:7.34%
cases:7.62%
controls:4.86%
cases:2.86%
controls:0.62%
—
—
—
—
cases:4.95%
controls:3.79%
cases:8.66%
controls:9.29%
23
154
187
1945
16
102
194
1997
6
13
204
2086
—
—
9
70
173
1778
11
113
116
1103
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
1.5e-01
1.2e+00
—
—
—
—
—
cases:2.38%
controls:2.05%
cases:2.86%
controls:0.86%
—
—
—
—
—
—
—
—
—
—
5
43
205
2056
6
18
204
2081
—
—
—
—
—
dexamethasone
S02BA06 [21605168]
—
-1.0e+50
—
—
—
-1.0e+50
5.9e-01
—
—
cases:0.00%
controls:1.29%
—
—
—
—
—
—
cases:0.00%
controls:0.54%
cases:3.94%
controls:2.22%
—
0
27
210
2072
—
—
—
0
10
182
1838
5
27
122
1189
Cytology report of Cervical or vaginal smear or scraping Cyto stain
47528-5 [3050380]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
8
127
1208
Allergic rhinitis due to pollen
J30.10 [2000502594]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
cases:0.00%
controls:0.82%
—
—
—
—
—
0
6
182
1842
0
10
127
1206
Fracture of lumbar vertebra
S32.0 [45583057]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
210
2092
—
—
—
—
—
—
Malignant neoplasm: Upper-outer quadrant of breast
C50.4 [45561816]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
210
2086
—
—
—
—
—
—
Glucose [Moles/volume] in Serum or Plasma --2 hours post meal
14761-1 [3012413]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
210
2093
—
—
—
—
—
—
Fungus identified in Specimen by Culture
580-1 [3000494]
-2.3e-01
5.2e-01
—
—
—
—
—
cases:3.33%
controls:4.14%
cases:2.86%
controls:1.72%
—
—
—
—
—
—
—
—
—
—
7
87
203
2012
6
36
204
2063
—
—
—
—
—
levofloxacin
S01AE05 [43534860]
4.6e-01
—
—
—
—
—
—
cases:3.81%
controls:2.43%
—
—
—
—
—
—
—
—
—
—
—
—
8
51
202
2048
—
—
—
—
—
—
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: occasional
SMOKING-1-1-2 [2002330117]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
210
2094
—
—
—
—
—
—
Supraventricular tachycardia
I47.1 [45567178]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
cases:0.00%
controls:0.74%
0
5
210
2094
—
—
—
—
0
6
182
1842
0
9
127
1207
tropicamide
S01FA06 [21605065]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
210
2091
—
—
—
—
—
—
Microorganisms panel - Urine sediment
58435-9 [40761536]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.29%
—
—
—
—
—
—
—
—
—
—
—
0
27
210
2072
—
—
—
—
—
Poisoning by systemic antibiotics
T36 [45756588]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
210
2094
—
—
—
—
—
—
Radiotherapy after total ablation of mammary gland
HA013 [2001303966]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
210
2094
—
—
—
—
—
—
ketoprofen; ointment
M02AA10 [21604046]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
0
22
210
2077
—
—
—
—
0
10
182
1838
—
Patella X-ray examination
NG2AA [2001308078]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
210
2092
—
—
—
—
—
—
Atrioventricular block, complete
I44.2 [45576872]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.48%
cases:0.00%
controls:0.38%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
cases:0.00%
controls:0.74%
0
10
210
2089
0
8
210
2091
—
—
—
0
9
182
1839
0
9
127
1207
Hemorrhoidectomy
JHB00 [2001305139]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
5
127
1211
Type 2 diabetes mellitus, with other specified complications
E11.6 [45552387]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
0
5
210
2094
—
—
—
—
0
6
127
1210
Supervision of pregnancy with other poor reproductive or obstetric history
Z35.2 [45585822]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
210
2093
—
—
—
—
—
—
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
3.3e-01
8.8e-01
—
—
—
—
—
cases:3.33%
controls:2.43%
cases:2.38%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
7
51
203
2048
5
21
205
2078
—
—
—
—
—
Palpitations/awareness of heart
K04 [2002000547]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
7
127
1209
Primary generalized (osteo)arthrosis
M15.0 [45543479]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
0
6
182
1842
—
Hypertension uncomplicated
K86 [2002000613]
2.0e-01
—
—
—
-1.0e+50
—
9.1e-01
cases:2.38%
controls:1.95%
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
cases:5.51%
controls:2.30%
5
41
205
2058
—
—
—
0
6
206
2072
—
7
28
120
1188
Amyloid beta 42 peptide [Mass/volume] in Cerebral spinal fluid
33203-1 [3042810]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
6
127
1210
Rhinopharyngoscopy
UDH02 [2001301680]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.62%
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
0
13
210
2086
0
5
210
2094
—
—
—
—
—
Therapeutic discussion
SPAT1240 [2001700341]
1.8e-01
—
—
—
—
—
—
cases:2.38%
controls:2.00%
—
—
—
—
—
—
—
—
—
—
—
—
5
42
205
2057
—
—
—
—
—
—
glibenclamide; oral
A10BB01 [21600750]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
0
5
210
2094
—
—
—
—
—
0
5
127
1211
Mycoplasma pneumoniae Ab [Units/volume] in Cerebral spinal fluid
17303-9 [3035929]
—
—
1.0e+50
1.0e+50
—
—
—
—
—
—
—
cases:2.38%
controls:0.00%
cases:2.38%
controls:0.00%
—
—
—
—
—
—
—
—
5
0
205
2099
5
0
205
2099
—
—
—
dydrogesterone; oral
G03DB01 [21602544]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
cases:0.00%
controls:0.76%
cases:0.00%
controls:0.49%
—
0
12
210
2087
—
—
—
0
14
182
1834
0
6
127
1210
phenylephrine, combinations
R01BA53 [21603214]
3.9e-01
—
—
—
-1.0e+50
—
—
cases:3.33%
controls:2.29%
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
7
48
203
2051
—
—
—
0
6
206
2072
—
—
duloxetine; oral
N06AX21 [21604749]
4.1e-01
—
—
—
-1.0e+50
—
—
cases:3.33%
controls:2.24%
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
7
47
203
2052
—
—
—
0
13
206
2065
—
—
Intraductal carcinoma in situ
D05.1 [45576374]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
210
2088
—
—
—
—
—
—
Obesity
E66 [45547648]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
0
12
210
2087
—
—
—
—
0
12
127
1204
JAK2 gene exon 14 targeted mutation analysis in Blood or Tissue by Molecular genetics method
80187-8 [21494670]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
210
2094
—
—
—
—
—
—
codeine; oral
R05DA04 [21603399]
-1.3e-02
—
—
—
—
—
—
cases:3.81%
controls:3.86%
—
—
—
—
—
—
—
—
—
—
—
—
8
81
202
2018
—
—
—
—
—
—
Polyp of nasal cavity
J33.0 [45562447]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
0
9
210
2090
—
—
—
—
—
0
5
127
1211
Essential tremor
G25.0 [45533132]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
0
9
210
2090
—
—
—
—
0
5
182
1843
—
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
1.5e-01
—
—
—
—
—
—
cases:3.81%
controls:3.29%
—
—
—
—
—
—
—
—
—
—
—
—
8
69
202
2030
—
—
—
—
—
—
alfuzosin; oral
G04CA01 [21602668]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.64%
—
—
—
—
—
—
0
20
127
1196
naratriptan; oral
N02CC02 [21604377]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
cases:0.00%
controls:0.41%
0
7
210
2092
—
—
—
—
0
5
182
1843
0
5
127
1211
Diastolic blood pressure
8462-4 [3012888]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
210
2093
—
—
—
—
—
—
mupirocin; nasal
R01AX06 [21603201]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
0
6
210
2093
—
—
—
—
—
Personal history of diseases of the digestive system
Z87.1 [45542474]
4.7e-02
—
—
—
-1.0e+50
2.6e-01
-3.4e-01
cases:15.71%
controls:15.10%
—
—
—
—
—
—
cases:0.00%
controls:0.48%
cases:4.40%
controls:3.41%
cases:7.87%
controls:10.69%
33
317
177
1782
—
—
—
0
10
206
2068
8
63
174
1785
10
130
117
1086
lithium; oral
N05AN01 [21604556]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
cases:0.00%
controls:0.41%
—
—
—
—
—
0
8
182
1840
0
5
127
1211
follitropin alfa; parenteral
G03GA05 [21602603]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
210
2093
—
—
—
—
—
—
selegiline; oral
N04BD01 [21604483]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
210
2094
—
—
—
—
—
—
HLA Ab [Presence] in Serum
44534-6 [3042733]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.33%
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
0
7
210
2092
0
6
210
2093
—
—
—
—
—
Bronchial lavation
TGC00 [2001303585]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
210
2093
—
—
—
—
—
—
Voice symptom/complaint
R23 [2002000892]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
210
2092
—
—
—
—
—
—
Demanding cystostatic therapy of methastized malignancy
WD125 [2001310680]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
0
6
210
2093
—
—
—
—
—
Melanocytic naevi of other and unspecified parts of face
D22.3 [45542687]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
210
2093
—
—
—
—
—
—
acrivastine; oral
R06AX18 [21603518]
-3.0e-01
—
—
—
-1.0e+50
-3.8e-01
3.7e-01
cases:8.10%
controls:10.67%
—
—
—
—
—
—
cases:0.00%
controls:0.38%
cases:2.75%
controls:3.95%
cases:10.24%
controls:7.32%
17
224
193
1875
—
—
—
0
8
206
2070
5
73
177
1775
13
89
114
1127
Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma
14685-2 [3009035]
-2.5e-01
-1.0e+50
—
—
-1.0e+50
—
-5.3e-01
cases:4.76%
controls:6.05%
cases:0.00%
controls:2.48%
—
—
—
—
cases:0.00%
controls:0.29%
—
—
cases:3.94%
controls:6.50%
10
127
200
1972
0
52
210
2047
—
—
0
6
206
2072
—
5
79
122
1137
Tumor of uncertain or unknown nature in the ovary without histology
D39.10 [2000501354]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
210
2093
—
—
—
—
—
—
fexofenadine; oral
R06AX26 [21603525]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.48%
cases:0.00%
controls:0.95%
—
—
—
—
cases:0.00%
controls:0.24%
cases:0.00%
controls:0.87%
cases:0.00%
controls:1.23%
0
31
210
2068
0
20
210
2079
—
—
0
5
206
2073
0
16
182
1832
0
15
127
1201
Long-term monitoring of blood pressure
SPAT1100 [2001700201]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.00%
cases:0.00%
controls:0.29%
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
0
21
210
2078
0
6
210
2093
—
—
—
0
10
182
1838
—
Implantation of transvenous cardiac pacemaker with atrial and ventricular electrodes
FPE20 [2001303170]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
0
7
210
2092
—
—
—
—
—
0
7
127
1209
Paediatric neurology
421 [44777781]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
210
2094
—
—
—
—
—
—
rubella, live attenuated
J07BJ01 [21601359]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
0
6
182
1842
—
Concussion
S06.0 [45582805]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
0
6
210
2093
—
—
—
—
—
Mycoplasma pneumoniae IgM Ab [Titer] in Cerebral spinal fluid
42991-0 [3037677]
—
—
1.0e+50
1.0e+50
1.0e+50
—
—
—
—
—
—
cases:3.33%
controls:0.00%
cases:5.24%
controls:0.00%
cases:2.43%
controls:0.00%
—
—
—
—
—
—
7
0
203
2099
11
0
199
2099
5
0
201
2078
—
—
Contraceptive management
Z30 [45756073]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
210
2094
—
—
—
—
—
—
Unstable angina
I20.09 [2000502389]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
0
7
210
2092
—
—
—
—
—
0
6
127
1210
Failure of genital response
F52.2 [45547715]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
210
2093
—
—
—
—
—
—
Occupational Medicine Clinic/Center
261QX0100X [38004267]
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:2.43%
controls:0.00%
—
—
—
—
—
—
—
—
5
0
201
2078
—
—
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: never
SMOKING-2-3-5 [2002330114]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
0
12
210
2087
—
—
—
—
—
acetylsalicylic acid; oral
B01AC06 [21600991]
-2.5e-01
-1.0e+50
-1.0e+50
—
-1.0e+50
—
—
cases:2.38%
controls:3.05%
cases:0.00%
controls:1.76%
cases:0.00%
controls:0.67%
—
—
cases:0.00%
controls:0.63%
—
—
—
—
5
64
205
2035
0
37
210
2062
0
14
210
2085
—
0
13
206
2065
—
—
clozapine; oral, parenteral
N05AH02 [21604542]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
210
2094
—
—
—
—
—
—
erdosteine; oral
R05CB15 [21603394]
2.5e-01
—
—
—
—
—
2.1e-01
cases:5.24%
controls:4.14%
—
—
—
—
—
—
—
—
—
—
cases:6.30%
controls:5.18%
11
87
199
2012
—
—
—
—
—
8
63
119
1153
Periodontitis pronounced
K05.31 [2000502729]
6.3e-01
—
—
—
—
—
—
cases:3.33%
controls:1.81%
—
—
—
—
—
—
—
—
—
—
—
—
7
38
203
2061
—
—
—
—
—
—
Allergy, unspecified
T78.4 [45580373]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
5
127
1211
Limited function/disability NOS
A28 [2002000162]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
0
9
210
2090
—
—
—
—
clonazepam; oral, parenteral
N03AE01 [21604415]
-1.0e+50
-1.0e+50
-1.0e+50
—
—
-1.0e+50
—
cases:0.00%
controls:1.00%
cases:0.00%
controls:0.62%
cases:0.00%
controls:0.29%
—
—
—
—
cases:0.00%
controls:0.70%
—
—
0
21
210
2078
0
13
210
2086
0
6
210
2093
—
—
0
13
182
1835
—
Acute sinusitis
J01 [45548098]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
0
12
127
1204
Elevated blood-pressure reading, without diagnosis of hypertension
R03.0 [45553712]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
0
6
182
1842
—
Candidiasis of vulva and vagina
B37.3 [45605230]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
210
2094
—
—
—
—
—
—
Thorax X-ray examination
GD1AA [2001303617]
-3.4e-01
-2.1e-02
—
1.0e+50
—
-1.9e-01
4.1e-01
cases:8.10%
controls:11.05%
cases:4.76%
controls:4.86%
—
—
cases:10.48%
controls:0.00%
—
—
cases:3.30%
controls:3.95%
cases:12.60%
controls:8.72%
17
232
193
1867
10
102
200
1997
—
22
0
188
2099
—
6
73
176
1775
16
106
111
1110
Preparatory care for dialysis
Z49.0 [45571361]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
210
2092
—
—
—
—
—
—
Cytology report of Tissue fine needle aspirate Cyto stain
33718-8 [3043109]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
0
6
210
2093
—
—
—
—
—
Fear of hypertension
K25 [2002000553]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
0
6
210
2093
—
—
—
—
—
paracetamol, combinations excl. psycholeptics
N02BE51 [21604348]
2.3e-01
-1.0e+50
—
—
—
-1.0e+50
—
cases:3.81%
controls:3.05%
cases:0.00%
controls:0.67%
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
8
64
202
2035
0
14
210
2085
—
—
—
0
11
182
1837
—
levodopa and decarboxylase inhibitor; oral
N04BA02 [21604465]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.86%
cases:0.00%
controls:0.57%
—
—
—
—
cases:0.00%
controls:0.29%
cases:0.00%
controls:0.54%
cases:0.00%
controls:0.58%
0
18
210
2081
0
12
210
2087
—
—
0
6
206
2072
0
10
182
1838
0
7
127
1209
Dermatographic urticaria
L50.3 [45596376]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
210
2094
—
—
—
—
—
—
Destruction of lesion of skin, site unspecified
QXA25 [2001310041]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
0
10
210
2089
—
—
—
—
—
0
5
127
1211
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]
3.3e-01
2.3e-01
—
—
—
7.6e-01
2.5e-01
cases:8.57%
controls:6.29%
cases:2.86%
controls:2.29%
—
—
—
—
—
—
cases:2.75%
controls:1.30%
cases:5.51%
controls:4.36%
18
132
192
1967
6
48
204
2051
—
—
—
5
24
177
1824
7
53
120
1163
Upper gastrointestinal surgery
106 [44777669]
1.0e-01
2.3e-01
-1.0e+50
—
—
4.0e-01
2.9e-01
cases:11.90%
controls:10.86%
cases:5.24%
controls:4.19%
cases:0.00%
controls:0.81%
—
—
—
—
cases:5.49%
controls:3.73%
cases:12.60%
controls:9.70%
25
228
185
1871
11
88
199
2011
0
17
210
2082
—
—
10
69
172
1779
16
118
111
1098
Achilles tendinitis
M76.6 [45596682]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
0
9
210
2090
—
—
—
—
—
Chronic asthma and similar chronic obstructive pulmonary diseases
203 [2001600201]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
0
12
210
2087
—
—
—
—
—
Laparoscopic unilateral salpingo-oophorectomy
LAF01 [2001306442]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
210
2094
—
—
—
—
—
—
vortioxetine; oral
N06AX26 [44819158]
2.5e-01
—
—
—
—
—
—
cases:2.38%
controls:1.86%
—
—
—
—
—
—
—
—
—
—
—
—
5
39
205
2060
—
—
—
—
—
—
Pulp capping
SGC10 [2001310393]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
7
127
1209
Other cervical disc degeneration
M50.3 [45582167]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
210
2094
—
—
—
—
—
—
Periodontal treatment by dental hygienist, extensive
SDE03 [2001310351]
3.7e-01
-1.0e+50
—
—
—
-1.0e+50
—
cases:4.29%
controls:3.00%
cases:0.00%
controls:0.62%
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
9
63
201
2036
0
13
210
2086
—
—
—
0
7
182
1841
—
Herpes simplex virus IgM Ab [Presence] in Serum by Immunoassay
40729-6 [3041145]
-1.0e+50
—
—
1.0e+50
1.0e+50
—
—
cases:0.00%
controls:0.29%
—
—
—
—
cases:2.86%
controls:0.00%
cases:4.85%
controls:0.00%
—
—
—
—
0
6
210
2093
—
—
6
0
204
2099
10
0
196
2078
—
—
Retained dental root
K08.3 [45543292]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
cases:0.00%
controls:0.66%
—
—
—
—
—
0
5
182
1843
0
8
127
1208
Ménière disease
H81.0 [45567143]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
6
127
1210
Cervical spine CT examination
NA1AD [2001306982]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
0
5
210
2094
—
—
—
—
—
Meningitis (in) Lyme disease
G01*A69.2 [2000502068]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:2.38%
controls:0.00%
—
—
—
—
—
—
—
—
—
5
0
205
2099
—
—
—
fluticasone; nasal
R01AD08 [21605050]
-4.9e-01
-3.3e-01
—
—
-1.0e+50
-5.9e-01
-3.8e-02
cases:8.10%
controls:12.58%
cases:3.33%
controls:4.57%
—
—
—
—
cases:0.00%
controls:0.67%
cases:2.75%
controls:4.87%
cases:8.66%
controls:8.96%
17
264
193
1835
7
96
203
2003
—
—
0
14
206
2064
5
90
177
1758
11
109
116
1107
solifenacin; oral
G04BD08 [21602641]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
0
5
182
1843
—
Other general examinations
Z00.8 [45581001]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
0
6
182
1842
—
insulin lispro; parenteral
A10AD04 [21600732]
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
cases:0.00%
controls:1.41%
—
—
—
—
—
—
0
5
206
2073
0
26
182
1822
—
Other arthrosis
M19 [45601352]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
6
127
1210
Remote contact by phone
ZYC01 [2001311579]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
0
8
210
2091
—
—
—
—
0
9
127
1207
dextromethorphan, combinations; oral
N07XX59 [43534835]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.48%
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
0
10
210
2089
0
7
210
2092
—
—
—
—
—
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
-4.2e-01
—
-1.0e+50
—
—
8.8e-01
4.1e-01
cases:4.76%
controls:7.10%
—
—
cases:0.00%
controls:0.48%
—
—
—
—
cases:3.85%
controls:1.62%
cases:7.87%
controls:5.35%
10
149
200
1950
—
0
10
210
2089
—
—
7
30
175
1818
10
65
117
1151
Heartburn
R12 [45539318]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.29%
cases:0.00%
controls:0.81%
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
0
27
210
2072
0
17
210
2082
—
—
—
0
8
182
1840
—
Intraoral radiographic dental examination
EB1AA [2001301903]
1.3e-01
-1.6e-01
-1.0e+50
—
—
-5.1e-01
3.9e-01
cases:22.38%
controls:20.15%
cases:4.76%
controls:5.53%
cases:0.00%
controls:0.29%
—
—
—
—
cases:3.30%
controls:5.36%
cases:19.69%
controls:14.23%
47
423
163
1676
10
116
200
1983
0
6
210
2093
—
—
6
99
176
1749
25
173
102
1043
Benign neoplasm: Transverse colon
D12.3 [45581282]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
—
—
—
—
0
8
127
1208
Concise certificate
WZA00 [2001310879]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
0
10
127
1206
SCL-70 extractable nuclear Ab [Units/volume] in Serum by Immunoassay
26975-3 [3025245]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
210
2086
—
—
—
—
—
—
Public health laboratory ask at order entry panel
81959-9 [21494755]
-6.4e-01
—
—
—
—
—
—
cases:2.86%
controls:5.29%
—
—
—
—
—
—
—
—
—
—
—
—
6
111
204
1988
—
—
—
—
—
—
Menopausal and other perimenopausal disorders
N95 [45582429]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.71%
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
0
15
210
2084
0
6
210
2093
—
—
—
—
—
Carboxyhemoglobin/Hemoglobin.total in Venous blood
2032-1 [3010517]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
cases:0.00%
controls:0.60%
cases:0.00%
controls:1.73%
—
0
12
210
2087
—
—
—
0
11
182
1837
0
21
127
1195
Aortic (valve) stenosis with insufficiency
I35.2 [45562346]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.38%
cases:0.00%
controls:0.24%
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
0
8
210
2091
0
5
210
2094
—
—
—
0
6
182
1842
—
Kappa light chains/Lambda light chains [Mass Ratio] in Serum
15189-4 [3007778]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
cases:0.00%
controls:0.27%
cases:0.00%
controls:0.74%
—
0
5
210
2094
—
—
—
0
5
182
1843
0
9
127
1207
hydrocortisone
S01BA02 [21603619]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
0
6
210
2093
—
—
—
—
—
0
6
127
1210
Plesiomonas shigelloides DNA [Presence] in Stool by NAA with non-probe detection
82198-3 [21493466]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
0
8
210
2091
—
—
—
—
—
0
6
127
1210
Cardiorespiratory global assessment
SPAT1081 [2001700182]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
5
127
1211
Treatment of a patient needing special arrangements
WYA30 [2001310874]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
0
6
210
2093
—
—
—
—
—
Unspecified injury of wrist and hand
S69.9 [45559703]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
210
2092
—
—
—
—
—
—
Lesion of ulnar nerve
G56.2 [45595951]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
210
2085
—
—
—
—
—
—
Unspecified acute lower respiratory infection
J22 [45586665]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.43%
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
0
9
210
2090
0
11
210
2088
—
—
—
—
—
Acute cystitis
N30.0 [45601724]
4.8e-01
—
—
—
—
—
—
cases:3.33%
controls:2.10%
—
—
—
—
—
—
—
—
—
—
—
—
7
44
203
2055
—
—
—
—
—
—
Ultrsound examination of lesion close to skin
QX3HE [2001310035]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
210
2094
—
—
—
—
—
—
prednisone
A07EA03 [21600655]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
0
5
210
2094
—
—
—
—
—
simvastatin; oral
C10AA01 [21601856]
-6.3e-02
-3.4e-01
—
—
—
-6.5e-01
-5.7e-01
cases:9.05%
controls:9.58%
cases:5.24%
controls:7.19%
—
—
—
—
—
—
cases:3.85%
controls:7.14%
cases:5.51%
controls:9.38%
19
201
191
1898
11
151
199
1948
—
—
—
7
132
175
1716
7
114
120
1102
Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep
18500-9 [3018006]
1.5e-01
—
—
—
—
—
1.9e-02
cases:6.19%
controls:5.38%
—
—
—
—
—
—
—
—
—
—
cases:3.94%
controls:3.87%
13
113
197
1986
—
—
—
—
—
5
47
122
1169
Remote monitoring CPAP
WX780 [2001310837]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
0
8
210
2091
—
—
—
0
7
182
1841
—
Ova and parasites identified in Stool by Light microscopy
10704-5 [3003327]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
0
8
210
2091
—
—
—
0
9
182
1839
—
Removal of sutures
SPAT1153 [2001700254]
-2.8e-01
—
—
—
—
—
3.2e-01
cases:5.24%
controls:6.81%
—
—
—
—
—
—
—
—
—
—
cases:7.09%
controls:5.26%
11
143
199
1956
—
—
—
—
—
9
64
118
1152
Other recurrent depressive disorders
F33.8 [45600740]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
210
2094
—
—
—
—
—
—
Palliative care
Z51.5 [45547323]
—
-1.0e+50
—
—
-1.0e+50
—
-1.0e+50
—
—
cases:0.00%
controls:0.29%
—
—
—
—
cases:0.00%
controls:0.24%
—
—
cases:0.00%
controls:0.66%
—
0
6
210
2093
—
—
0
5
206
2073
—
0
8
127
1208
Type 1 diabetes mellitus
E10 [45576436]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
6
127
1210
Hip X-ray examination
NF1AA [2001307894]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
0
20
210
2079
—
—
—
—
0
6
182
1842
—
Total cardiopulmonary bypass in normothermia or moderate hypothermia at concurrent surgical procedure
FXA00 [2001303347]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.38%
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
0
8
210
2091
0
5
210
2094
—
—
—
—
—
Mild depressive episode without somatic syndrome
F32.00 [2000501978]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
6
127
1210
Kappa light chains.free [Mass/volume] in Serum
36916-5 [3034860]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
cases:0.00%
controls:0.27%
cases:0.00%
controls:0.74%
—
0
5
210
2094
—
—
—
0
5
182
1843
0
9
127
1207
Dementia
P70 [2002000864]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
6
127
1210
Dust mix specific IgE antibody measurement
849121000000107 [44813793]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
210
2093
—
—
—
—
—
—
Acute stress reaction mild
F43.00 [2000501998]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
210
2091
—
—
—
—
—
—
Undifferentiated schizophrenia continuous
F20.30 [2000501944]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
0
6
210
2093
—
—
—
—
—
Benzodiazepines [Presence] in Urine
3390-2 [3000764]
1.3e+00
-1.0e+50
—
—
—
-1.0e+50
—
cases:3.81%
controls:1.05%
cases:0.00%
controls:0.33%
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
8
22
202
2077
0
7
210
2092
—
—
—
0
9
182
1839
—
Leukocytes [#/area] in Urine sediment by Automated count
46702-7 [3051014]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
210
2094
—
—
—
—
—
—
phenylpropanolamine, combinations; oral
R01BA51 [21603212]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.52%
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
0
11
210
2088
0
7
210
2092
—
—
—
—
—
Rectal bleeding
D16 [2002000315]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
210
2093
—
—
—
—
—
—
Preventive oral health care, extensive
SCA03 [2001310304]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
7
127
1209
Cystitis
N30 [45563012]
5.9e-01
—
—
—
—
—
—
cases:2.38%
controls:1.33%
—
—
—
—
—
—
—
—
—
—
—
—
5
28
205
2071
—
—
—
—
—
—
bisoprolol and thiazides
C07BB07 [21601714]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
cases:0.00%
controls:0.32%
cases:0.00%
controls:0.49%
—
0
5
210
2094
—
—
—
0
6
182
1842
0
6
127
1210
Seronegative rheumatoid arthritis
M06.0 [45577103]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
0
9
127
1207

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
79
21
58.43
133.58
1.1
1.4
—
—
—
0
0
91
40
38.33
132.53
1.1
1.3
—
—
—
0
0
82
51
25.17
102.20
1.1
1.3
69.05
2479.87
e6/l
0.54
40
39
80
50
24.70
99.32
1.1
1.2
93.11
4.94
e6/l
3.51
36
36
117
148
15.90
96.61
3.4
2.6
21.62
12.08
au/ml
0.99
23
15
112
134
16.13
95.98
1.8
1.3
61.99
22.03
au/ml
1.64
16
11
61
25
33.49
89.35
1.1
1.4
—
—
—
0
0
44
21
26.00
60.03
1.1
1.1
—
—
—
0
0
141
499
6.17
39.17
3.3
4.7
—
—
—
0
0
33
13
29.65
24.82
1.2
1.3
2.19
1.85
mmol/l
0.81
33
13
122
660
2.93
13.66
5.7
6.1
—
—
—
0
0
148
944
2.77
11.22
6.4
6.6
8.88
8.65
%
0.39
140
890
147
940
2.73
10.99
6.4
6.6
0.57
0.71
%
2.66
139
877
147
954
2.66
10.43
6.4
6.5
57.62
57.65
%
0.01
141
914
70
319
2.76
10.32
2.5
3.1
4.01
2.11
e6/l
0.42
22
142
145
947
2.59
9.95
6.4
6.5
2.23
2.88
%
1.87
137
891
146
968
2.54
9.52
6.5
6.6
26.01
27.65
%
0.83
140
922
122
747
2.44
9.47
3.8
3.9
21.35
76.45
e6/l
1.45
77
524
15
11
14.53
9.33
1.1
1.0
—
—
—
0
0
19
39
5.24
9.02
1.0
1.3
260.42
246.00
u/ml
0.08
12
15
24
63
4.16
8.50
1.2
1.4
—
—
—
0
0
152
1063
2.42
8.26
6.8
6.9
0.14
0.19
e9/l
4.60
132
927
149
1035
2.39
8.19
6.6
6.6
0.04
0.04
e9/l
1.37
124
879
148
1029
2.36
8.06
6.6
6.6
0.57
0.57
e9/l
0.04
123
877
150
1055
2.35
7.86
6.6
6.6
1.71
1.79
e9/l
0.35
128
925
97
571
2.26
7.84
2.7
3.1
0.27
0.43
e6/l
0.71
57
409
157
1137
2.36
7.52
8.5
10.5
4.26
4.05
e9/l
0.36
130
980
127
848
2.19
7.36
6.7
6.3
1.20
1.22
mmol/l
2.38
115
792
105
656
2.16
7.15
2.9
3.2
30.63
150.02
e6/l
0.63
70
497
16
23
7.42
7.14
1.0
1.2
—
—
—
0
0
186
1482
2.74
6.76
8.1
8.4
73.56
79.70
u/l
1.31
181
1417
144
1048
2.10
6.22
5.5
7.0
10.66
11.13
umol/l
0.33
138
1002
67
383
2.08
5.49
1.7
2.0
—
—
—
0
0
130
938
1.96
5.44
7.1
7.2
1.20
1.21
mmol/l
0.86
116
825
110
762
1.90
5.09
2.3
2.1
—
—
—
0
0
89
584
1.89
4.80
2.4
2.7
—
0.18
—
0
11
209
1890
3.56
4.67
19.0
15.3
20.99
23.04
mg/l
0.51
198
1546
33
153
2.36
4.46
3.2
4.6
7.40
7.36
ph
0.85
21
111
15
39
4.05
4.29
1.0
1.3
186.00
157.65
au/ml
—
5
13
61
368
1.91
4.17
3.4
3.9
85.84
189.36
ng/l
0.56
45
280
7
8
8.99
3.80
1.1
1.0
1200.86
1639.63
miu/ml
—
7
8
38
200
2.09
3.79
3.1
2.6
33.82
34.03
u/l
0.02
33
163
109
802
1.72
3.77
2.2
2.0
98.65
96.71
pmol/l
0.14
57
405
108
809
1.66
3.38
3.6
4.8
35.24
36.00
g/l
0.83
102
769
109
829
1.63
3.14
2.8
3.4
6.19
6.19
ph
0.01
45
479
30
158
2.04
2.98
1.5
1.8
6.50
6.08
ph
—
9
110
25
123
2.17
2.95
1.5
2.4
—
—
—
0
0
25
123
2.17
2.95
1.0
1.1
—
—
—
0
0
66
452
1.66
2.83
1.3
1.4
1.94
2.52
g/l
2.15
34
271
130
1050
1.59
2.80
2.9
3.8
0.00
0.00
estimate
-0.00
12
211
64
441
1.64
2.66
1.6
1.7
0.92
1.32
mg/l
0.90
45
350
128
1038
1.56
2.65
3.0
3.7
128.25
7.89
estimate
0.43
12
238
11
36
3.16
2.60
1.2
1.1
—
—
—
0
0
11
36
3.16
2.60
1.2
1.1
—
—
—
0
0
127
1031
1.56
2.59
3.0
3.7
0.00
0.00
estimate
-0.00
11
233
35
207
1.82
2.49
13.3
7.7
7.42
7.42
ph
0.00
15
120
80
594
1.55
2.40
2.5
4.1
7.41
7.40
ph
1.41
56
431
34
203
1.80
2.35
13.6
7.9
1.45
1.02
mmol/l
0.30
27
175
75
552
1.55
2.33
1.6
1.6
19.71
21.51
nmol/l
0.60
62
470
105
841
1.48
2.14
9.7
11.9
1.18
1.19
inr
0.08
79
701
10
37
2.78
2.10
1.1
1.1
—
—
—
0
0
81
618
1.49
2.09
7.2
6.2
—
—
—
0
0
5
10
5.09
2.08
3.6
1.7
369.60
991.10
u/ml
—
5
10
22
119
1.94
2.06
18.7
7.9
25.08
24.75
mmol/l
0.20
22
119
80
611
1.49
2.05
2.1
2.5
52.04
71.98
u/l
1.20
74
575
20
105
2.00
2.03
1.4
1.2
—
—
—
0
0
9
32
2.89
2.02
1.0
1.1
—
—
—
0
0
10
39
2.64
1.97
1.3
1.6
—
—
—
0
0
111
912
1.44
1.92
2.9
3.0
122.42
115.03
ug/l
0.15
101
862
62
456
1.50
1.89
2.2
2.6
5.18
5.16
e6/l
0.01
56
414
8
30
2.73
1.74
1.4
1.2
—
—
—
0
0
22
127
1.81
1.72
19.4
10.0
94.67
93.52
%
0.42
22
127
10
41
2.51
1.66
1.1
1.1
—
—
—
0
0
77
606
1.42
1.63
2.5
2.2
—
—
—
0
0
8
32
2.56
1.61
2.0
1.7
—
—
—
0
0
7
26
2.75
1.59
1.3
1.4
—
—
—
0
0
15
78
1.99
1.58
1.2
1.5
—
—
—
0
0
28
178
1.66
1.58
15.3
8.5
—
—
—
0
0
39
270
1.54
1.56
12.3
7.2
104.15
104.40
mmol/l
0.14
39
270
109
917
1.38
1.54
9.4
11.3
0.00
0.00
e9/l
0.01
81
748
5
15
3.39
1.53
1.6
1.6
—
—
—
0
0
13
65
2.06
1.52
1.1
1.1
—
—
—
0
0
18
102
1.83
1.50
1.3
3.2
0.51
0.61
%
1.04
18
102
7
154
0.44
1.50
4.0
4.3
1.23
1.22
mmol/l
—
7
138
7
155
0.43
1.49
3.3
3.5
—
—
—
0
0
12
59
2.09
1.46
1.3
1.2
—
—
—
0
0
6
22
2.77
1.44
1.2
1.3
—
—
—
0
0
43
310
1.48
1.43
1.3
1.4
111.11
563.33
titre
—
9
72
15
82
1.89
1.39
1.2
1.5
—
—
—
0
0
28
185
1.59
1.37
1.6
4.1
1.80
1.78
mmol/l
0.01
23
154
6
23
2.65
1.37
1.2
1.3
26.17
24.81
ng/l
—
6
23
5
17
2.98
1.36
3.6
2.5
35.28
37.23
%
—
5
17
154
1385
1.38
1.36
3.2
3.3
50.92
46.60
u/l
0.29
149
1317
29
194
1.57
1.35
1.7
1.9
—
—
—
0
0
15
83
1.87
1.35
1.2
1.5
—
—
—
0
0
6
24
2.54
1.31
1.2
1.3
—
—
—
0
0
15
84
1.84
1.30
1.2
1.5
—
—
—
0
0
15
84
1.84
1.30
1.2
1.5
—
—
—
0
0
67
822
0.73
1.30
3.0
3.1
—
—
—
0
0
5
18
2.82
1.29
1.6
2.4
—
—
—
0
0
88
732
1.34
1.28
3.2
3.7
54.35
33.55
ng/l
0.25
63
500
65
516
1.37
1.28
2.4
2.8
334.11
341.65
umol/l
0.24
57
469
187
1746
1.50
1.28
5.7
5.3
1.68
1.92
mu/l
2.55
172
1623
25
164
1.59
1.27
1.9
2.7
0.23
0.22
g/l
0.45
25
153
28
189
1.55
1.27
1.7
4.0
7.38
7.39
ph
0.16
12
111
162
1477
1.38
1.25
4.2
4.3
14.73
14.71
pmol/l
0.03
146
1363
17
103
1.71
1.16
1.4
3.2
0.86
1.14
%
1.63
17
103
7
30
2.38
1.13
1.0
1.4
—
—
—
0
0
7
30
2.38
1.13
1.0
1.4
—
—
—
0
0
7
30
2.38
1.13
1.0
1.4
—
—
—
0
0
7
30
2.38
1.13
1.0
1.4
—
—
—
0
0
7
31
2.30
1.11
1.9
1.6
—
—
—
0
0
34
248
1.44
1.08
1.5
1.7
—
—
—
0
0
42
319
1.39
1.07
1.6
1.6
—
—
—
0
0
14
83
1.73
1.04
1.5
1.7
—
—
—
0
0
7
34
2.09
1.04
2.4
1.8
—
—
—
0
0
59
476
1.33
1.03
2.2
2.1
2.99
2.75
mg/l
0.23
48
412
5
23
2.20
0.98
3.2
4.3
2.36
3.15
nmol/l
—
5
23
49
388
1.34
0.97
2.5
2.7
512.05
538.38
mosm/kgh2o
0.37
44
339
63
518
1.30
0.96
2.4
2.9
—
—
—
0
0
60
493
1.30
0.92
1.3
1.3
0.52
1.13
u/ml
2.02
13
139
24
169
1.47
0.92
1.2
1.2
—
—
—
0
0
17
111
1.58
0.91
1.1
1.7
—
5.23
—
0
24
212
2069
1.90
0.86
28.2
23.3
134.21
136.62
g/l
2.15
212
2055
212
2067
1.93
0.85
27.9
23.2
6.63
6.65
e9/l
0.04
206
2031
212
2067
1.93
0.85
27.9
23.2
4.46
4.54
e12/l
1.41
206
2029
212
2067
1.93
0.85
29.8
23.6
39.86
40.80
%
1.94
212
2053
212
2067
1.93
0.85
27.8
23.1
30.35
30.34
pg
0.02
212
2055
212
2067
1.93
0.85
27.9
23.2
247.44
251.12
e9/l
0.37
207
2034
212
2066
1.95
0.85
27.8
23.1
90.79
90.93
fl
0.16
212
2054
23
165
1.44
0.82
2.5
3.3
90.99
74.66
e9/l
0.82
14
117
14
90
1.59
0.80
2.6
2.3
—
—
—
0
0
23
167
1.42
0.77
1.5
1.5
—
—
—
0
0
0
28
0.00
0.76
0.0
2.8
—
—
—
0
0
47
567
0.78
0.76
3.4
4.0
0.00
0.00
estimate
—
9
217
5
24
2.11
0.75
1.0
1.2
—
—
—
0
0
33
257
1.33
0.74
1.6
1.6
—
—
—
0
0
6
109
0.54
0.74
2.0
2.7
37.93
65.80
u/ml
—
6
104
38
464
0.78
0.67
4.3
5.2
—
—
—
0
0
23
173
1.37
0.65
1.8
1.8
3.81
3.57
mmol/l
0.40
15
126
35
281
1.29
0.65
1.6
2.1
—
—
—
0
0
9
140
0.63
0.62
1.7
1.2
168.01
350.08
u/ml
—
9
128
44
366
1.25
0.62
1.3
1.3
1.35
7.71
u/ml
2.20
13
144
48
407
1.23
0.57
1.4
1.3
61.98
28.76
iu/ml
—
10
137
5
90
0.55
0.57
1.0
1.1
—
—
—
0
0
72
637
1.19
0.56
3.9
3.5
2.33
2.35
mmol/l
0.53
61
584
6
37
1.64
0.56
1.0
1.6
—
—
—
0
0
96
873
1.18
0.55
2.6
2.6
—
—
estimate
—
0
0
70
784
0.84
0.54
2.8
3.6
0.00
0.00
estimate
—
7
199
6
39
1.55
0.53
3.0
3.1
20.50
37.23
u/ml
—
6
39
202
1967
1.37
0.53
13.6
13.0
—
—
—
0
0
61
537
1.19
0.50
1.4
1.4
—
—
—
0
0
188
1817
1.25
0.50
4.7
4.2
1.22
1.31
mmol/l
1.17
170
1699
5
31
1.63
0.43
1.4
1.1
—
—
—
0
0
29
241
1.23
0.43
1.5
1.6
—
—
—
0
0
45
392
1.19
0.42
3.7
3.1
0.44
0.74
ug/l
4.44
25
242
40
347
1.19
0.39
2.4
2.7
2.44
2.45
mmol/l
0.20
33
308
11
80
1.39
0.39
1.0
1.2
—
—
—
0
0
0
19
0.00
0.39
0.0
2.5
—
—
—
0
0
57
630
0.87
0.36
3.1
4.0
4.73
9.10
mg/mmol
1.28
33
401
56
619
0.87
0.35
2.9
3.4
41.63
51.49
mg/l
0.26
32
409
31
266
1.19
0.35
1.2
1.2
—
—
—
0
0
11
82
1.36
0.35
1.7
1.6
282.64
315.24
mu/l
0.22
11
76
6
44
1.37
0.34
1.0
1.4
—
—
—
0
0
68
625
1.13
0.32
6.6
5.1
2.85
1.80
ug/l
0.49
57
566
53
582
0.88
0.30
2.2
3.0
0.00
0.00
estimate
—
8
189
20
167
1.22
0.29
1.3
1.4
—
—
—
0
0
32
281
1.16
0.28
1.5
1.7
744.59
1203.54
nmol/l
3.10
22
218
8
62
1.30
0.28
1.3
1.6
—
6.19
—
0
15
28
246
1.16
0.25
1.3
1.3
—
—
—
0
0
6
82
0.72
0.24
4.2
3.1
1.55
1.51
%
—
6
76
0
11
0.00
0.21
0.0
1.3
—
190.45
—
0
11
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
11
89
1.25
0.21
2.8
3.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
0.12
—
0
7
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
20
227
0.87
0.19
1.4
1.6
—
—
—
0
0
5
68
0.73
0.17
1.0
2.2
—
—
—
0
0
9
78
1.16
0.15
1.2
1.4
0.97
1.15
g/l
—
9
73
12
103
1.17
0.14
1.5
1.5
0.11
0.27
mg/l
—
5
42
82
850
0.94
0.13
2.2
2.0
1.49
1.40
mmol/l
0.37
66
729
5
47
1.07
0.09
5.6
3.7
—
—
—
0
0
25
233
1.08
0.09
1.8
1.3
—
—
—
0
0
47
452
1.05
0.07
2.8
3.8
1.02
1.02
kg/l
0.86
32
303
24
226
1.07
0.07
2.3
1.8
323.75
394.95
nmol/l
1.25
24
213
178
1795
0.95
0.06
6.0
6.1
38.35
39.11
mmol/mol
0.56
166
1716
191
1898
1.05
0.05
5.8
5.1
4.83
4.68
mmol/l
1.18
176
1797
182
1832
0.96
0.04
5.1
4.9
5.86
5.91
mmol/l
0.13
165
1705
191
1921
0.95
0.04
6.3
5.7
2.88
2.77
mmol/l
0.91
172
1815
11
102
1.08
0.03
3.3
4.5
—
—
—
0
0
190
1891
1.04
0.02
5.6
5.0
1.51
1.45
mmol/l
1.22
174
1781
163
1639
0.98
0.02
24.5
18.8
13.46
13.54
%
0.32
163
1632
12
114
1.06
0.01
1.8
1.7
—
—
—
0
0
12
126
0.95
0.00
1.4
1.2
—
—
—
0
0
66
665
0.99
0.00
2.6
3.2
8.14
8.19
mmol/l
0.02
52
567
24
235
1.02
0.00
1.2
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
0.00
0.0
2.8
—
5.26
—
0
8
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
5
50
1.00
0.00
1.4
1.3
0.78
0.91
nmol/l
—
5
41
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
7
69
1.01
-0.00
6.4
3.3
1.04
0.85
%
—
7
63
0
9
0.00
-0.00
0.0
1.0
—
38.14
—
0
9
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
1.19
—
0
5
0
5
0.00
-0.00
0.0
4.4
—
53.40
—
0
5
0
5
0.00
-0.00
0.0
5.2
—
12.72
—
0
5
0
5
0.00
-0.00
0.0
1.6
—
40.80
—
0
5
0
5
0.00
-0.00
0.0
2.6
—
2.16
—
0
5
0
5
0.00
-0.00
0.0
3.0
—
2140.00
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
0.02
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: AB1_TICK_BORNE_ENCEPHALITIS_WIDE – Tick-borne viral encephalitis, including avohilmo

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).